{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T00:33:31Z","timestamp":1794270811069,"version":"4.9.0"},"reference-count":393,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T00:00:00Z","timestamp":1777939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T00:00:00Z","timestamp":1777939200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100011305","name":"UAB | Comprehensive Cancer Center, University of Alabama at Birmingham","doi-asserted-by":"publisher","award":["5P30CAO13148-47"],"award-info":[{"award-number":["5P30CAO13148-47"]}],"id":[{"id":"10.13039\/100011305","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011305","name":"UAB | Comprehensive Cancer Center, University of Alabama at Birmingham","doi-asserted-by":"publisher","award":["5P30CAO13148-47"],"award-info":[{"award-number":["5P30CAO13148-47"]}],"id":[{"id":"10.13039\/100011305","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal and aggressive tumor types, with a dismal 5-year survival rate of less than 15%. Despite major advances in understanding PDAC biology, therapeutic progress has been limited. Numerous preclinical studies have provided encouraging evidence that immune-based therapies may be effective. However, the clinical translation of immunotherapies for PDAC treatment has proven difficult with a lack of favorable tumor responses outside of a very select group of patients such as patients with MSI high tumors. Immune checkpoint inhibitors, as well as combination strategies with targeted radiotherapy or chemotherapy, have largely failed to demonstrate meaningful survival benefits for the majority of PDAC patients. Increasing evidence indicates that PDAC harbors a uniquely complex and multifaceted immunosuppressive microenvironment, which plays a central role in shielding malignant cells from effective antitumor immunity. Overcoming this barrier requires the development of rational and effective combination regimens that simultaneously target both the tumor and its surrounding immune microenvironment. Novel strategies, including the use of natural killer cell\u2013based therapies, reprogramming of cancer-associated fibroblasts, and integration of predictive or prognostic biomarkers, hold promise for enhancing therapeutic efficacy. This review summarizes recent progress in PDAC immunotherapy, highlights key challenges, and discusses emerging approaches designed to improve patient outcomes.<\/jats:p>","DOI":"10.1038\/s41392-026-02705-5","type":"journal-article","created":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T00:01:36Z","timestamp":1777939296000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Pancreatic ductal adenocarcinoma: integrating molecular insights for targeted interventions"],"prefix":"10.1038","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4989-5234","authenticated-orcid":false,"given":"Ganji Purnachandra","family":"Nagaraju","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haasita","family":"Nellipudi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaithanya","family":"Ganji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vaishnavi","family":"Kuppala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swapna Priya","family":"Ganji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seema","family":"Kumari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Batoul","family":"Farran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mundla","family":"Srilatha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachael","family":"Guenter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2661-5746","authenticated-orcid":false,"given":"Bassel F.","family":"El-Rayes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,5]]},"reference":[{"key":"2705_CR1","first-page":"10","volume":"75","author":"RL Siegel","year":"2025","unstructured":"Siegel, R. L. et al. Cancer statistics, 2025. CA Cancer J. Clin. 75, 10 (2025).","journal-title":"CA Cancer J. Clin."},{"key":"2705_CR2","doi-asserted-by":"publisher","first-page":"217699","DOI":"10.1016\/j.canlet.2025.217699","volume":"622","author":"K Br\u00e4utigam","year":"2025","unstructured":"Br\u00e4utigam, K. et al. Tumor immune microenvironment in pancreatic ductal adenocarcinoma revisited-exploring the \u201cSpace\u201d. Cancer Lett. 622, 217699 (2025).","journal-title":"Cancer Lett."},{"key":"2705_CR3","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1158\/1535-7163.MCT-24-0311","volume":"24","author":"EF Giurini","year":"2025","unstructured":"Giurini, E. F., Ralph, O., Pappas, S. G. & Gupta, K. H. Looking Beyond Checkpoint Inhibitor Monotherapy: Uncovering New Frontiers for Pancreatic Cancer Immunotherapy. Mol. Can. Ther. 24, 18\u201332 (2025).","journal-title":"Mol. Can. Ther."},{"key":"2705_CR4","doi-asserted-by":"publisher","first-page":"2056","DOI":"10.1053\/j.gastro.2018.12.038","volume":"156","author":"VP Balachandran","year":"2019","unstructured":"Balachandran, V. P., Beatty, G. L. & Dougan, S. K. Broadening the impact of immunotherapy to pancreatic cancer: challenges and opportunities. Gastroenterology 156, 2056\u20132072 (2019).","journal-title":"Gastroenterology"},{"key":"2705_CR5","doi-asserted-by":"publisher","first-page":"111584","DOI":"10.1016\/j.cellsig.2024.111584","volume":"127","author":"JY Kwon","year":"2025","unstructured":"Kwon, J. Y., Vera, R. E. & Fernandez-Zapico, M. E. The multi-faceted roles of cancer-associated fibroblasts in pancreatic cancer. Cell Signal. 127, 111584 (2025).","journal-title":"Cell Signal."},{"key":"2705_CR6","doi-asserted-by":"publisher","first-page":"101881","DOI":"10.1016\/j.xcrm.2024.101881","volume":"6","author":"GP Nagaraju","year":"2025","unstructured":"Nagaraju, G. P. et al. Mechanism of enhancing chemotherapy efficacy in pancreatic ductal adenocarcinoma with paricalcitol and hydroxychloroquine. Cell Rep. Med. 6, 101881 (2025).","journal-title":"Cell Rep. Med."},{"key":"2705_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-024-02208-3","volume":"24","author":"S He","year":"2025","unstructured":"He, S., Zheng, L. & Qi, C. Myeloid-derived suppressor cells (MDSCs) in the tumor microenvironment and their targeting in cancer therapy. Mol. Cancer 24, 5 (2025).","journal-title":"Mol. Cancer"},{"key":"2705_CR8","doi-asserted-by":"publisher","first-page":"100743","DOI":"10.1016\/j.tranon.2020.01.004","volume":"13","author":"A Bulle","year":"2020","unstructured":"Bulle, A. et al. Gemcitabine recruits M2-type tumor-associated macrophages into the stroma of pancreatic cancer. Transl. Oncol. 13, 100743 (2020).","journal-title":"Transl. Oncol."},{"key":"2705_CR9","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s13402-022-00741-1","volume":"46","author":"YH Zhu","year":"2023","unstructured":"Zhu, Y. H. et al. Immunosuppression, immune escape, and immunotherapy in pancreatic cancer: focused on the tumor microenvironment. Cell Oncol. 46, 17\u201348 (2023).","journal-title":"Cell Oncol."},{"key":"2705_CR10","doi-asserted-by":"publisher","first-page":"2014","DOI":"10.1158\/2159-8290.CD-20-0841","volume":"11","author":"SM Liudahl","year":"2021","unstructured":"Liudahl, S. M. et al. Leukocyte heterogeneity in pancreatic ductal adenocarcinoma: phenotypic and spatial features associated with clinical outcome. Cancer Discov. 11, 2014\u20132031 (2021).","journal-title":"Cancer Discov."},{"key":"2705_CR11","doi-asserted-by":"publisher","first-page":"e2400050","DOI":"10.1200\/OA-24-00050","volume":"1","author":"JM Finan","year":"2024","unstructured":"Finan, J. M., Guo, Y., Goodyear, S. M. & Brody, J. R. Challenges and opportunities in targeting the complex pancreatic tumor microenvironment. JCO Oncol. Adv. 1, e2400050 (2024).","journal-title":"JCO Oncol. Adv."},{"key":"2705_CR12","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.cytogfr.2022.09.001","volume":"68","author":"T Luong","year":"2022","unstructured":"Luong, T., Golivi, Y., Nagaraju, G. P. & El-Rayes, B. F. Fibroblast heterogeneity in pancreatic ductal adenocarcinoma: Perspectives in immunotherapy. Cytokine Growth Factor Rev. 68, 107\u2013115 (2022).","journal-title":"Cytokine Growth Factor Rev."},{"key":"2705_CR13","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1053\/j.gastro.2004.12.036","volume":"128","author":"MG Bachem","year":"2005","unstructured":"Bachem, M. G. et al. Pancreatic carcinoma cells induce fibrosis by stimulating proliferation and matrix synthesis of stellate cells. Gastroenterology 128, 907\u2013921 (2005).","journal-title":"Gastroenterology"},{"key":"2705_CR14","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1084\/jem.20162024","volume":"214","author":"D \u00d6hlund","year":"2017","unstructured":"\u00d6hlund, D. et al. Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer. J. Exp. Med. 214, 579\u2013596 (2017).","journal-title":"J. Exp. Med."},{"key":"2705_CR15","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1158\/2159-8290.CD-19-0094","volume":"9","author":"E Elyada","year":"2019","unstructured":"Elyada, E. et al. Cross-species single-cell analysis of pancreatic ductal adenocarcinoma reveals antigen-presenting cancer-associated fibroblasts. Cancer Discov. 9, 1102\u20131123 (2019).","journal-title":"Cancer Discov."},{"key":"2705_CR16","doi-asserted-by":"publisher","first-page":"3505","DOI":"10.1158\/0008-5472.CAN-24-2860","volume":"84","author":"ES Carpenter","year":"2024","unstructured":"Carpenter, E. S. et al. Pancreatic Cancer\u2013associated Fibroblasts: where do we go from here?. Cancer Res. 84, 3505\u20133508 (2024).","journal-title":"Cancer Res."},{"key":"2705_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-022-05351-1","volume":"13","author":"T Zhang","year":"2022","unstructured":"Zhang, T. et al. Cancer-associated fibroblasts in pancreatic ductal adenocarcinoma. Cell Death Dis. 13, 897 (2022).","journal-title":"Cell Death Dis."},{"key":"2705_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01876-x","volume":"22","author":"C Ma","year":"2023","unstructured":"Ma, C. et al. Pan-cancer spatially resolved single-cell analysis reveals the crosstalk between cancer-associated fibroblasts and tumor microenvironment. Mol. Cancer 22, 170 (2023).","journal-title":"Mol. Cancer"},{"key":"2705_CR19","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1002\/path.5926","volume":"257","author":"S Menezes","year":"2022","unstructured":"Menezes, S. et al. Cancer-associated fibroblasts in pancreatic cancer: new subtypes, new markers, new targets. J. Pathol. 257, 526\u2013544 (2022).","journal-title":"J. Pathol."},{"key":"2705_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-025-06744-4","volume":"23","author":"Y Li","year":"2025","unstructured":"Li, Y. et al. Paracrine signaling in cancer-associated fibroblasts: central regulators of the tumor immune microenvironment. J. Transl. Med. 23, 697 (2025).","journal-title":"J. Transl. Med."},{"key":"2705_CR21","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-022-01569-x","volume":"21","author":"D Peng","year":"2022","unstructured":"Peng, D. et al. Targeting TGF-\u03b2 signal transduction for fibrosis and cancer therapy. Mol. Cancer 21, 104 (2022).","journal-title":"Mol. Cancer"},{"key":"2705_CR22","doi-asserted-by":"publisher","first-page":"107256","DOI":"10.1016\/j.jbc.2024.107256","volume":"300","author":"K Miyazawa","year":"2024","unstructured":"Miyazawa, K., Itoh, Y., Fu, H. & Miyazono, K. Receptor-activated transcription factors and beyond: multiple modes of Smad2\/3-dependent transmission of TGF-\u03b2 signaling. J. Biol. Chem. 300, 107256 (2024).","journal-title":"J. Biol. Chem."},{"key":"2705_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-024-05411-4","volume":"22","author":"AO Giarratana","year":"2024","unstructured":"Giarratana, A. O., Prendergast, C. M., Salvatore, M. M. & Capaccione, K. M. TGF-\u03b2 signaling: critical nexus of fibrogenesis and cancer. J. Transl. Med. 22, 594 (2024).","journal-title":"J. Transl. Med."},{"key":"2705_CR24","doi-asserted-by":"publisher","first-page":"316","DOI":"10.37349\/etat.2023.00137","volume":"4","author":"MK-K Chan","year":"2023","unstructured":"Chan, M. K.-K. et al. Transforming growth factor-\u03b2 signaling: from tumor microenvironment to anticancer therapy. Expl Target Antitumor Ther. 4, 316 (2023).","journal-title":"Expl Target Antitumor Ther."},{"key":"2705_CR25","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41571-020-0403-1","volume":"18","author":"R Derynck","year":"2021","unstructured":"Derynck, R., Turley, S. J. & Akhurst, R. J. TGF\u03b2 biology in cancer progression and immunotherapy. Nat. Rev. Clin. Oncol. 18, 9\u201334 (2021).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2705_CR26","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-024-01623-9","volume":"22","author":"DB Gumede","year":"2024","unstructured":"Gumede, D. B., Abrahamse, H. & Houreld, N. N. Targeting Wnt\/\u03b2-catenin signaling and its interplay with TGF-\u03b2 and Notch signaling pathways for the treatment of chronic wounds. Cell Commun. Signal. 22, 244 (2024).","journal-title":"Cell Commun. Signal."},{"key":"2705_CR27","first-page":"e2018","volume":"7","author":"N Yang","year":"2024","unstructured":"Yang, N., Hellevik, T., Berzaghi, R. & Martinez-Zubiaurre, I. Radiation-induced effects on TGF-\u03b2 and PDGF receptor signaling in cancer-associated fibroblasts. Cancer Rep. 7, e2018 (2024).","journal-title":"Cancer Rep."},{"key":"2705_CR28","doi-asserted-by":"publisher","first-page":"216859","DOI":"10.1016\/j.canlet.2024.216859","volume":"591","author":"Q Qin","year":"2024","unstructured":"Qin, Q. et al. Cancer-associated fibroblasts in pancreatic ductal adenocarcinoma therapy: challenges and opportunities. Cancer Lett. 591, 216859 (2024).","journal-title":"Cancer Lett."},{"key":"2705_CR29","doi-asserted-by":"publisher","first-page":"4371","DOI":"10.1038\/s41388-022-02432-5","volume":"41","author":"S D\u2019Agosto","year":"2022","unstructured":"D\u2019Agosto, S. et al. Loss of FGFR4 promotes the malignant phenotype of PDAC. Oncogene 41, 4371\u20134384 (2022).","journal-title":"Oncogene"},{"key":"2705_CR30","doi-asserted-by":"publisher","first-page":"2358","DOI":"10.1016\/j.celrep.2019.07.092","volume":"28","author":"P Bordignon","year":"2019","unstructured":"Bordignon, P. et al. Dualism of FGF and TGF-\u03b2 signaling in heterogeneous cancer-associated fibroblast activation with ETV1 as a critical determinant. Cell Rep. 28, 2358\u20132372.e2356 (2019).","journal-title":"Cell Rep."},{"key":"2705_CR31","first-page":"100","volume":"3","author":"H Tang","year":"2023","unstructured":"Tang, H. et al. Heterogeneity and function of cancer-associated fibroblasts in renal cell carcinoma. J. Nat. Can. Cen. 3, 100\u2013105 (2023).","journal-title":"J. Nat. Can. Cen."},{"key":"2705_CR32","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/s10555-020-09952-0","volume":"40","author":"AA Khan","year":"2021","unstructured":"Khan, A. A. et al. An overview of genetic mutations and epigenetic signatures in the course of pancreatic cancer progression. Cancer Metastasis Rev. 40, 245\u2013272 (2021).","journal-title":"Cancer Metastasis Rev."},{"key":"2705_CR33","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/s41575-020-0300-1","volume":"17","author":"AN Hosein","year":"2020","unstructured":"Hosein, A. N., Brekken, R. A. & Maitra, A. Pancreatic cancer stroma: an update on therapeutic targeting strategies. Nat. Rev. Gastroenterol. Hepatol. 17, 487\u2013505 (2020).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"2705_CR34","doi-asserted-by":"publisher","first-page":"2101428","DOI":"10.1002\/adhm.202101428","volume":"11","author":"X Xu","year":"2022","unstructured":"Xu, X. et al. Nanomedicine strategies to circumvent intratumor extracellular matrix barriers for cancer therapy. Adv. Health. Mater. 11, 2101428 (2022).","journal-title":"Adv. Health. Mater."},{"key":"2705_CR35","doi-asserted-by":"publisher","first-page":"146","DOI":"10.3390\/ijms23010146","volume":"23","author":"S Niland","year":"2021","unstructured":"Niland, S., Riscanevo, A. X. & Eble, J. A. Matrix metalloproteinases shape the tumor microenvironment in cancer progression. Int. J. Mol. Sci. 23, 146 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"2705_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10555-024-10186-7","volume":"43","author":"T Guo","year":"2024","unstructured":"Guo, T. & Xu, J. Cancer-associated fibroblasts: a versatile mediator in tumor progression, metastasis, and targeted therapy. Cancer Metastasis Rev. 43, 1\u201322 (2024).","journal-title":"Cancer Metastasis Rev."},{"key":"2705_CR37","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1016\/j.cell.2016.03.029","volume":"165","author":"CJ Tape","year":"2016","unstructured":"Tape, C. J. et al. Oncogenic KRAS regulates tumor cell signaling via stromal reciprocation. Cell 165, 910\u2013920 (2016).","journal-title":"Cell"},{"key":"2705_CR38","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1038\/ncb2756","volume":"15","author":"F Calvo","year":"2013","unstructured":"Calvo, F. et al. Mechanotransduction and YAP-dependent matrix remodelling is required for the generation and maintenance of cancer-associated fibroblasts. Nat. Cell Biol. 15, 637\u2013646 (2013).","journal-title":"Nat. Cell Biol."},{"key":"2705_CR39","doi-asserted-by":"publisher","first-page":"2525","DOI":"10.1158\/0008-5472.CAN-15-1293","volume":"76","author":"DR Principe","year":"2016","unstructured":"Principe, D. R. et al. TGF\u03b2 signaling in the pancreatic tumor microenvironment promotes fibrosis and immune evasion to facilitate tumorigenesis. Cancer Res. 76, 2525\u20132539 (2016).","journal-title":"Cancer Res."},{"key":"2705_CR40","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/nature16064","volume":"527","author":"X Zheng","year":"2015","unstructured":"Zheng, X. et al. Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer. Nature 527, 525\u2013530 (2015).","journal-title":"Nature"},{"key":"2705_CR41","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1038\/s12276-023-01013-0","volume":"55","author":"D Yang","year":"2023","unstructured":"Yang, D., Liu, J., Qian, H. & Zhuang, Q. Cancer-associated fibroblasts: from basic science to anticancer therapy. Exp. Mol. Med. 55, 1322\u20131332 (2023).","journal-title":"Exp. Mol. Med."},{"key":"2705_CR42","doi-asserted-by":"publisher","first-page":"10.20517","DOI":"10.20517\/2394-4722.2022.60","volume":"8","author":"M Diab","year":"2022","unstructured":"Diab, M. & El-Rayes, B. F. The heterogeneity of CAFs and immune cell populations in the tumor microenvironment of pancreatic adenocarcinoma. J. Cancer Metastasis Treat. 8, 10.20517 (2022).","journal-title":"J. Cancer Metastasis Treat."},{"key":"2705_CR43","first-page":"6","volume":"6","author":"K-Y Li","year":"2020","unstructured":"Li, K.-Y. et al. Pancreatic ductal adenocarcinoma immune microenvironment and immunotherapy prospects. Chin. Med. J. Transl. Med. 6, 6\u201317 (2020).","journal-title":"Chin. Med. J. Transl. Med."},{"key":"2705_CR44","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-021-01428-1","volume":"20","author":"X Mao","year":"2021","unstructured":"Mao, X. et al. Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives. Mol. Cancer 20, 131 (2021).","journal-title":"Mol. Cancer"},{"key":"2705_CR45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/imm.13496","volume":"167","author":"Z Zhang","year":"2022","unstructured":"Zhang, Z. et al. Heterogeneous cancer-associated fibroblasts: a new perspective for understanding immunosuppression in pancreatic cancer. Immunol 167, 1\u201314 (2022).","journal-title":"Immunol"},{"key":"2705_CR46","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.molmed.2023.03.002","volume":"29","author":"R Rebelo","year":"2023","unstructured":"Rebelo, R., Xavier, C. P., Giovannetti, E. & Vasconcelos, M. H. Fibroblasts in pancreatic cancer: molecular and clinical perspectives. Trends Mol. Med. 29, 439\u2013453 (2023).","journal-title":"Trends Mol. Med."},{"key":"2705_CR47","doi-asserted-by":"publisher","first-page":"420","DOI":"10.3390\/biom10030420","volume":"10","author":"M Mijit","year":"2020","unstructured":"Mijit, M. et al. Role of p53 in the regulation of cellular senescence. Biomolecules 10, 420 (2020).","journal-title":"Biomolecules"},{"key":"2705_CR48","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1007\/s10522-025-10249-4","volume":"26","author":"SN Pandey","year":"2025","unstructured":"Pandey, S. N. et al. ATM and p53 in aging and cancer: A double-edged sword in genomic integrity. Biogerontology 26, 102 (2025).","journal-title":"Biogerontology"},{"key":"2705_CR49","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1007\/s10522-025-10194-2","volume":"26","author":"AK Balaraman","year":"2025","unstructured":"Balaraman, A. K. et al. The interplay of p16INK4a and non-coding RNAs: bridging cellular senescence, aging, and cancer. Biogerontology 26, 50 (2025).","journal-title":"Biogerontology"},{"key":"2705_CR50","volume-title":"Senescent Carcinoma Associated Fibroblasts Up-regulate Interleukin 8 to Enhance Pancreatic Cancer Progression","author":"T Wang","year":"2015","unstructured":"Wang, T. Senescent Carcinoma Associated Fibroblasts Up-regulate Interleukin 8 to Enhance Pancreatic Cancer Progression. University of Toronto: Canada, 2015."},{"key":"2705_CR51","doi-asserted-by":"publisher","first-page":"111689","DOI":"10.1016\/j.mad.2022.111689","volume":"206","author":"E Bientinesi","year":"2022","unstructured":"Bientinesi, E. et al. Doxorubicin-induced senescence in normal fibroblasts promotes in vitro tumour cell growth and invasiveness: the role of Quercetin in modulating these processes. Mech. Ageing Dev. 206, 111689 (2022).","journal-title":"Mech. Ageing Dev."},{"key":"2705_CR52","doi-asserted-by":"publisher","first-page":"254","DOI":"10.3390\/ijms23010254","volume":"23","author":"M Cortesi","year":"2021","unstructured":"Cortesi, M. et al. Pancreatic cancer and cellular senescence: tumor microenvironment under the spotlight. Int. J. Mol. Sci. 23, 254 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"2705_CR53","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1007\/s12029-024-01111-w","volume":"55","author":"S Rafaqat","year":"2024","unstructured":"Rafaqat, S. et al. Role of interleukins in pancreatic cancer: a literature review. J. Gastrointest. Cancer 55, 1498\u20131510 (2024).","journal-title":"J. Gastrointest. Cancer"},{"key":"2705_CR54","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1080\/14728222.2021.2015321","volume":"25","author":"Z Zhang","year":"2021","unstructured":"Zhang, Z. & Zhang, H.-J. Glycometabolic rearrangements\u2013aerobic glycolysis in pancreatic ductal adenocarcinoma (PDAC): roles, regulatory networks, and therapeutic potential. Expert Opin. Ther. Targets 25, 1077\u20131093 (2021).","journal-title":"Expert Opin. Ther. Targets"},{"key":"2705_CR55","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1038\/s41421-021-00271-4","volume":"7","author":"Y Wang","year":"2021","unstructured":"Wang, Y. et al. Single-cell analysis of pancreatic ductal adenocarcinoma identifies a novel fibroblast subtype associated with poor prognosis but better immunotherapy response. Cell Disc. 7, 36 (2021).","journal-title":"Cell Disc."},{"key":"2705_CR56","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1186\/s13046-023-02934-4","volume":"42","author":"R Melchionna","year":"2023","unstructured":"Melchionna, R. et al. Transcription factors in fibroblast plasticity and CAF heterogeneity. J. Exp. Clin. Cancer Res. 42, 347 (2023).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"2705_CR57","first-page":"1","volume":"25","author":"M Shakiba","year":"2025","unstructured":"Shakiba, M. & Tuveson, D. A. Macrophages and fibroblasts as regulators of the immune response in pancreatic cancer. Nat. Immunol. 25, 1\u201314 (2025).","journal-title":"Nat. Immunol."},{"key":"2705_CR58","doi-asserted-by":"publisher","first-page":"13408","DOI":"10.3390\/ijms222413408","volume":"22","author":"U Vaish","year":"2021","unstructured":"Vaish, U., Jain, T., Are, A. C. & Dudeja, V. Cancer-associated fibroblasts in pancreatic ductal adenocarcinoma: an update on heterogeneity and therapeutic targeting. Int. J. Mol. Sci. 22, 13408 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"2705_CR59","doi-asserted-by":"publisher","first-page":"887380","DOI":"10.3389\/fimmu.2022.887380","volume":"13","author":"L Koppensteiner","year":"2022","unstructured":"Koppensteiner, L., Mathieson, L., O\u2019Connor, R. A. & Akram, A. R. Cancer associated fibroblasts-an impediment to effective anti-cancer T cell immunity. Front. Immunol. 13, 887380 (2022).","journal-title":"Front. Immunol."},{"key":"2705_CR60","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s13046-025-03290-1","volume":"44","author":"F Ren","year":"2025","unstructured":"Ren, F. et al. Myeloid cell-derived apCAFs promote HNSCC progression by regulating proportion of CD4+ and CD8+ T cells. J. Exp. Clin. Cancer Res. 44, 33 (2025).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"2705_CR61","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-57465-7","volume":"16","author":"J Song","year":"2025","unstructured":"Song, J. et al. Antigen-presenting cancer associated fibroblasts enhance antitumor immunity and predict immunotherapy response. Nat. Commun. 16, 2175 (2025).","journal-title":"Nat. Commun."},{"key":"2705_CR62","doi-asserted-by":"publisher","unstructured":"Maru, S. Y. et al. Antigen-presenting cancer-associated fibroblasts in murine pancreatic tumors differentially control regulatory T cell phenotype and function via CXCL9 and CCL22. Preprint at https:\/\/doi.org\/10.1101\/2025.03.27.645833 (2025).","DOI":"10.1101\/2025.03.27.645833"},{"key":"2705_CR63","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s10555-023-10079-1","volume":"42","author":"K Cole","year":"2023","unstructured":"Cole, K., Al-Kadhimi, Z. & Talmadge, J. E. Role of myeloid-derived suppressor cells in tumor recurrence. Cancer Metastasis Rev. 42, 113\u2013142 (2023).","journal-title":"Cancer Metastasis Rev."},{"key":"2705_CR64","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01813-y","volume":"22","author":"SK Gautam","year":"2023","unstructured":"Gautam, S. K., Batra, S. K. & Jain, M. Molecular and metabolic regulation of immunosuppression in metastatic pancreatic ductal adenocarcinoma. Mol. Cancer 22, 118 (2023).","journal-title":"Mol. Cancer"},{"key":"2705_CR65","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41423-019-0306-1","volume":"17","author":"K Nakamura","year":"2020","unstructured":"Nakamura, K. & Smyth, M. J. Myeloid immunosuppression and immune checkpoints in the tumor microenvironment. Cell Mol. Immunol. 17, 1\u201312 (2020).","journal-title":"Cell Mol. Immunol."},{"key":"2705_CR66","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12032-019-1329-2","volume":"37","author":"R Tamura","year":"2020","unstructured":"Tamura, R. et al. The role of vascular endothelial growth factor in the hypoxic and immunosuppressive tumor microenvironment: perspectives for therapeutic implications. Med. Oncol. 37, 1\u201314 (2020).","journal-title":"Med. Oncol."},{"key":"2705_CR67","doi-asserted-by":"publisher","first-page":"216391","DOI":"10.1016\/j.canlet.2023.216391","volume":"574","author":"O Li","year":"2023","unstructured":"Li, O. et al. Biological characteristics of pancreatic ductal adenocarcinoma: initiation to malignancy, intracellular to extracellular. Cancer Lett. 574, 216391 (2023).","journal-title":"Cancer Lett."},{"key":"2705_CR68","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1007\/s44272-023-00005-5","volume":"2","author":"T Zhu","year":"2023","unstructured":"Zhu, T. et al. The role of innate immune cells as modulators of the tumor microenvironment in the metastasis and treatment of pancreatic cancer. Clin. Cancer Bull. 2, 2 (2023).","journal-title":"Clin. Cancer Bull."},{"key":"2705_CR69","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.semcancer.2023.09.004","volume":"96","author":"J Fyfe","year":"2023","unstructured":"Fyfe, J. et al. Immune evasion on the nanoscale: small extracellular vesicles in pancreatic ductal adenocarcinoma immunity. Semin Cancer Biol. 96, 36\u201347 (2023).","journal-title":"Semin Cancer Biol."},{"key":"2705_CR70","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1111\/sji.12242","volume":"80","author":"Y Ohshio","year":"2014","unstructured":"Ohshio, Y., Hanaoka, J., Kontani, K. & Teramoto, K. Tranilast inhibits the function of cancer-associated fibroblasts responsible for the induction of immune suppressor cell types. Scand. J. Immunol. 80, 408\u2013416 (2014).","journal-title":"Scand. J. Immunol."},{"key":"2705_CR71","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1016\/j.ccell.2017.10.005","volume":"32","author":"V Kumar","year":"2017","unstructured":"Kumar, V. et al. Cancer-associated fibroblasts neutralize the anti-tumor effect of CSF1 receptor blockade by inducing PMN-MDSC infiltration of tumors. Cancer Cell. 32, 654\u2013668. e655 (2017).","journal-title":"Cancer Cell."},{"key":"2705_CR72","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1186\/s40425-019-0734-6","volume":"7","author":"R Trovato","year":"2019","unstructured":"Trovato, R. et al. Immunosuppression by monocytic myeloid-derived suppressor cells in patients with pancreatic ductal carcinoma is orchestrated by STAT3. J. Immunother. Cancer 7, 255 (2019).","journal-title":"J. Immunother. Cancer"},{"key":"2705_CR73","doi-asserted-by":"publisher","first-page":"2794","DOI":"10.7150\/thno.111180","volume":"15","author":"X Tong","year":"2025","unstructured":"Tong, X. et al. The TMBIM1-YBX1 axis orchestrates MDSC recruitment and immunosuppressive microenvironment in pancreatic cancer. Theranostics 15, 2794\u20132813 (2025).","journal-title":"Theranostics"},{"key":"2705_CR74","doi-asserted-by":"publisher","first-page":"111576","DOI":"10.1016\/j.cellsig.2024.111576","volume":"127","author":"R Liu","year":"2025","unstructured":"Liu, R. et al. Tumor cells induce neural DKK1 expression to promote MDSC infiltration and subsequent T cell suppression. Cell Signal. 127, 111576 (2025).","journal-title":"Cell Signal."},{"key":"2705_CR75","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/s41575-021-00475-9","volume":"18","author":"LA Rojas","year":"2021","unstructured":"Rojas, L. A. & Balachandran, V. P. Scaling the immune incline in PDAC. Nat. Rev. Gastroenterol. Hepatol. 18, 453\u2013454 (2021).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"2705_CR76","doi-asserted-by":"publisher","first-page":"e2406748121","DOI":"10.1073\/pnas.2406748121","volume":"121","author":"A Dahal","year":"2024","unstructured":"Dahal, A. et al. Platelet-activating factor (PAF) promotes immunosuppressive neutrophil differentiation within tumors. Proc. Natl. Acad. Sci. USA 121, e2406748121 (2024).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2705_CR77","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1136\/gutjnl-2022-329349","volume":"72","author":"X Liu","year":"2023","unstructured":"Liu, X. et al. CRIP1 fosters MDSC trafficking and resets tumour microenvironment via facilitating NF-\u03baB\/p65 nuclear translocation in pancreatic ductal adenocarcinoma. Gut 72, 2329\u20132343 (2023).","journal-title":"Gut"},{"key":"2705_CR78","doi-asserted-by":"publisher","first-page":"3193","DOI":"10.1016\/j.ymthe.2023.09.010","volume":"31","author":"R Sun","year":"2023","unstructured":"Sun, R. et al. CXCR4-modified CAR-T cells suppresses MDSCs recruitment via STAT3\/NF-\u03baB\/SDF-1\u03b1 axis to enhance efficacy against pancreatic cancer. Mol. Ther. 31, 3193\u20133209 (2023).","journal-title":"Mol. Ther."},{"key":"2705_CR79","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1007\/s00262-022-03334-x","volume":"72","author":"Y Kajiwara","year":"2023","unstructured":"Kajiwara, Y. et al. Oncolytic virus-mediated reducing of myeloid-derived suppressor cells enhances the efficacy of PD-L1 blockade in gemcitabine-resistant pancreatic cancer. Cancer Immunol. Immunother. 72, 1285\u20131300 (2023).","journal-title":"Cancer Immunol. Immunother."},{"key":"2705_CR80","volume-title":"Exploring Tumor-Associated Macrophage Heterogeneity and Their Responses to MEK Inhibition in Pancreatic Ductal Adenocarcinoma","author":"C Neander","year":"2020","unstructured":"Neander, C. Exploring Tumor-Associated Macrophage Heterogeneity and Their Responses to MEK Inhibition in Pancreatic Ductal Adenocarcinoma. Universit\u00e4t Duisburg-Essen: Duisburg, Essen, 2020). Dissertation."},{"key":"2705_CR81","doi-asserted-by":"publisher","first-page":"583084","DOI":"10.3389\/fimmu.2020.583084","volume":"11","author":"Y Pan","year":"2020","unstructured":"Pan, Y., Yu, Y., Wang, X. & Zhang, T. Tumor-associated macrophages in tumor immunity. Front. Immunol. 11, 583084 (2020).","journal-title":"Front. Immunol."},{"key":"2705_CR82","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1111\/febs.14295","volume":"285","author":"M Mazzone","year":"2018","unstructured":"Mazzone, M., Menga, A. & Castegna, A. Metabolism and TAM functions\u2014it takes two to tango. FEBS J. 285, 700\u2013716 (2018).","journal-title":"FEBS J."},{"key":"2705_CR83","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1002\/ijc.34270","volume":"151","author":"S Magri","year":"2022","unstructured":"Magri, S. et al. The immunosuppression pathway of tumor-associated macrophages is controlled by heme oxygenase-1 in glioblastoma patients. Int. J. Cancer 151, 2265\u20132277 (2022).","journal-title":"Int. J. Cancer"},{"key":"2705_CR84","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12943-023-01725-x","volume":"22","author":"H Zhang","year":"2023","unstructured":"Zhang, H. et al. Roles of tumor-associated macrophages in anti-PD-1\/PD-L1 immunotherapy for solid cancers. Mol. Cancer 22, 1\u201323 (2023).","journal-title":"Mol. Cancer"},{"key":"2705_CR85","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/S0198-8859(99)00158-5","volume":"61","author":"MC Mingari","year":"2000","unstructured":"Mingari, M. C. et al. Expression of HLA class I-specific inhibitory receptors in human cytolytic T lymphocytes: a regulated mechanism that controls T-cell activation and function. Hum. Immunol. 61, 44\u201350 (2000).","journal-title":"Hum. Immunol."},{"key":"2705_CR86","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01737-7","volume":"22","author":"Y Zhou","year":"2023","unstructured":"Zhou, Y., Cheng, L., Liu, L. & Li, X. NK cells are never alone: crosstalk and communication in tumour microenvironments. Mol. Cancer 22, 34 (2023).","journal-title":"Mol. Cancer"},{"key":"2705_CR87","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/s41586-023-06685-2","volume":"623","author":"N Caronni","year":"2023","unstructured":"Caronni, N. et al. IL-1\u03b2+ macrophages fuel pathogenic inflammation in pancreatic cancer. Nature 623, 415\u2013422 (2023).","journal-title":"Nature"},{"key":"2705_CR88","doi-asserted-by":"publisher","first-page":"122838","DOI":"10.1016\/j.biomaterials.2024.122838","volume":"314","author":"S Tabe","year":"2025","unstructured":"Tabe, S. et al. A pancreatic cancer organoid incorporating macrophages reveals the correlation between the diversity of tumor-associated macrophages and cancer cell survival. Biomaterials 314, 122838 (2025).","journal-title":"Biomaterials"},{"key":"2705_CR89","doi-asserted-by":"publisher","first-page":"216784","DOI":"10.1016\/j.canlet.2024.216784","volume":"588","author":"Z Zhong","year":"2024","unstructured":"Zhong, Z. et al. Tumor-associated macrophages drive glycolysis through the IL-8\/STAT3\/GLUT3 signaling pathway in pancreatic cancer progression. Cancer Lett. 588, 216784 (2024).","journal-title":"Cancer Lett."},{"key":"2705_CR90","doi-asserted-by":"publisher","first-page":"e010029","DOI":"10.1136\/jitc-2024-010029","volume":"13","author":"H Xu","year":"2025","unstructured":"Xu, H. et al. CREB3L1 facilitates pancreatic tumor progression and reprograms intratumoral tumor-associated macrophages to shape an immunotherapy-resistance microenvironment. J. Immunother. Cancer 13, e010029 (2025).","journal-title":"J. Immunother. Cancer"},{"key":"2705_CR91","doi-asserted-by":"publisher","first-page":"111590","DOI":"10.1016\/j.intimp.2024.111590","volume":"129","author":"Y Chen","year":"2024","unstructured":"Chen, Y. et al. Macrophage-derived exosomal microRNAs promote metastasis in pancreatic ductal adenocarcinoma. Int. Immunopharmacol. 129, 111590 (2024).","journal-title":"Int. Immunopharmacol."},{"key":"2705_CR92","doi-asserted-by":"publisher","first-page":"189065","DOI":"10.1016\/j.bbcan.2023.189065","volume":"1879","author":"M Chakkera","year":"2024","unstructured":"Chakkera, M., Foote, J. B., Farran, B. & Nagaraju, G. P. Breaking the stromal barrier in pancreatic cancer: advances and challenges. Biochim. Biophys. Acta Rev. Cancer 1879, 189065 (2024).","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"2705_CR93","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-022-01657-y","volume":"21","author":"Y Wu","year":"2022","unstructured":"Wu, Y. et al. Myeloid-derived suppressor cells: an emerging target for anticancer immunotherapy. Mol. Cancer 21, 184 (2022).","journal-title":"Mol. Cancer"},{"key":"2705_CR94","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1158\/0008-5472.CAN-12-2202","volume":"73","author":"A Sawant","year":"2013","unstructured":"Sawant, A. et al. Myeloid-derived suppressor cells function as novel osteoclast progenitors enhancing bone loss in breast cancer. Cancer Res. 73, 672\u2013682 (2013).","journal-title":"Cancer Res."},{"key":"2705_CR95","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.cpt.2024.07.004","volume":"3","author":"R Liu","year":"2025","unstructured":"Liu, R. et al. Tumor-associated macrophages (TAMs): constructing an immunosuppressive microenvironment bridge for pancreatic ductal adenocarcinoma (PDAC)\u2606. Cancer Pathog. Ther. 3, 183\u2013196 (2025).","journal-title":"Cancer Pathog. Ther."},{"key":"2705_CR96","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-024-00522-z","volume":"8","author":"S Wang","year":"2024","unstructured":"Wang, S. et al. Targeting M2-like tumor-associated macrophages is a potential therapeutic approach to overcome antitumor drug resistance. NPJ Precis. Oncol. 8, 31 (2024).","journal-title":"NPJ Precis. Oncol."},{"key":"2705_CR97","doi-asserted-by":"publisher","first-page":"4456","DOI":"10.1016\/j.apsb.2025.07.021","volume":"15","author":"A-Q Li","year":"2025","unstructured":"Li, A.-Q. et al. Understanding the complexity of tumor-associated macrophages: druggable and therapeutic insights. Acta Pharm. Sin. B. 15, 4456\u20134475 (2025).","journal-title":"Acta Pharm. Sin. B."},{"key":"2705_CR98","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-023-01388-7","volume":"22","author":"Z Hussain","year":"2024","unstructured":"Hussain, Z. et al. Macrophages reprogramming driven by cancer-associated fibroblasts under FOLFIRINOX treatment correlates with shorter survival in pancreatic cancer. Cell Commun. Signal. 22, 1 (2024).","journal-title":"Cell Commun. Signal."},{"key":"2705_CR99","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1016\/j.cell.2023.02.014","volume":"186","author":"CJ Halbrook","year":"2023","unstructured":"Halbrook, C. J., Lyssiotis, C. A., di Magliano, M. P. & Maitra, A. Pancreatic cancer: advances and challenges. Cell 186, 1729\u20131754 (2023).","journal-title":"Cell"},{"key":"2705_CR100","first-page":"1","volume":"37","author":"SA Desai","year":"2023","unstructured":"Desai, S. A. et al. The tumor microenvironment: shaping cancer progression and treatment response. J. Chemother. 37, 1\u201330 (2023).","journal-title":"J. Chemother."},{"key":"2705_CR101","doi-asserted-by":"publisher","first-page":"281","DOI":"10.4062\/biomolther.2024.029","volume":"32","author":"DU Lee","year":"2024","unstructured":"Lee, D. U., Han, B. S., Jung, K. H. & Hong, S.-S. Tumor stroma as a therapeutic target for pancreatic ductal adenocarcinoma. Biomol. Ther. 32, 281\u2013290 (2024).","journal-title":"Biomol. Ther."},{"key":"2705_CR102","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1002\/ijc.34921","volume":"154","author":"H Wang","year":"2024","unstructured":"Wang, H. et al. Shaping the immune-suppressive microenvironment on tumor-associated myeloid cells through tumor-derived exosomes. Int. J. Cancer 154, 2031\u20132042 (2024).","journal-title":"Int. J. Cancer"},{"key":"2705_CR103","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-024-00681-z","volume":"8","author":"Y Ju","year":"2024","unstructured":"Ju, Y. et al. Barriers and opportunities in pancreatic cancer immunotherapy. NPJ Precis Oncol. 8, 199 (2024).","journal-title":"NPJ Precis Oncol."},{"key":"2705_CR104","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1038\/s41420-024-01807-9","volume":"10","author":"S Zhang","year":"2024","unstructured":"Zhang, S. et al. Fatty acid metabolism of immune cells: a new target of tumour immunotherapy. Cell Death Discov. 10, 39 (2024).","journal-title":"Cell Death Discov."},{"key":"2705_CR105","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.immuni.2017.12.004","volume":"48","author":"F Zhao","year":"2018","unstructured":"Zhao, F. et al. Paracrine Wnt5a-\u03b2-catenin signaling triggers a metabolic program that drives dendritic cell tolerization. Immunity 48, 147\u2013160.e147 (2018).","journal-title":"Immunity"},{"key":"2705_CR106","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/s13045-023-01498-2","volume":"16","author":"HR Jin","year":"2023","unstructured":"Jin, H. R. et al. Lipid metabolic reprogramming in tumor microenvironment: from mechanisms to therapeutics. J. Hematol. Oncol. 16, 103 (2023).","journal-title":"J. Hematol. Oncol."},{"key":"2705_CR107","doi-asserted-by":"publisher","first-page":"eadp3978","DOI":"10.1126\/sciimmunol.adp3978","volume":"10","author":"GD Hogg","year":"2025","unstructured":"Hogg, G. D. et al. Combined Flt3L and CD40 agonism restores dendritic cell\u2013driven T cell immunity in pancreatic cancer. Sci. Immunol. 10, eadp3978 (2025).","journal-title":"Sci. Immunol."},{"key":"2705_CR108","doi-asserted-by":"crossref","unstructured":"Zeltz, C. et al. Cancer-associated fibroblasts in desmoplastic tumors: emerging role of integrins. Semin.Cancer Biol. 62, 166\u2013181 (2020).","DOI":"10.1016\/j.semcancer.2019.08.004"},{"key":"2705_CR109","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1038\/s41571-020-0363-5","volume":"17","author":"WJ Ho","year":"2020","unstructured":"Ho, W. J., Jaffee, E. M. & Zheng, L. The tumour microenvironment in pancreatic cancer\u2014clinical challenges and opportunities. Nat. Rev. Clin. Oncol. 17, 527\u2013540 (2020).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2705_CR110","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.ejca.2017.06.016","volume":"83","author":"P Lohneis","year":"2017","unstructured":"Lohneis, P. et al. Cytotoxic tumour-infiltrating T lymphocytes influence outcome in resected pancreatic ductal adenocarcinoma. Eur. J. Cancer 83, 290\u2013301 (2017).","journal-title":"Eur. J. Cancer"},{"key":"2705_CR111","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1038\/nri1248","volume":"3","author":"O Acuto","year":"2003","unstructured":"Acuto, O. & Michel, F. CD28-mediated co-stimulation: a quantitative support for TCR signalling. Nat. Rev. Immunol. 3, 939\u2013951 (2003).","journal-title":"Nat. Rev. Immunol."},{"key":"2705_CR112","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1038\/s41590-023-01733-5","volume":"25","author":"D Wilfahrt","year":"2024","unstructured":"Wilfahrt, D. & Delgoffe, G. M. Metabolic waypoints during T cell differentiation. Nat. Immunol. 25, 206\u2013217 (2024).","journal-title":"Nat. Immunol."},{"key":"2705_CR113","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1038\/s41435-025-00340-8","volume":"26","author":"Y Liu","year":"2025","unstructured":"Liu, Y. et al. Regulation of CD4+ T cell differentiation and function by glucose metabolism. Genes Immun. 26, 287\u2013296 (2025).","journal-title":"Genes Immun."},{"key":"2705_CR114","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-024-05552-6","volume":"22","author":"X Su","year":"2024","unstructured":"Su, X. et al. Strategies to enhance the therapeutic efficacy of anti-PD-1 antibody, anti-PD-L1 antibody and anti-CTLA-4 antibody in cancer therapy. J. Transl. Med. 22, 751 (2024).","journal-title":"J. Transl. Med."},{"key":"2705_CR115","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.immuni.2024.01.013","volume":"57","author":"KP Burke","year":"2024","unstructured":"Burke, K. P., Chaudhri, A., Freeman, G. J. & Sharpe, A. H. The B7: CD28 family and friends: unraveling coinhibitory interactions. Immunity 57, 223\u2013244 (2024).","journal-title":"Immunity"},{"key":"2705_CR116","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1158\/2326-6066.CIR-13-0216","volume":"2","author":"H-J Kim","year":"2014","unstructured":"Kim, H.-J. & Cantor, H. CD4 T-cell subsets and tumor immunity: the helpful and the not-so-helpful. Cancer Immunol. Res. 2, 91\u201398 (2014).","journal-title":"Cancer Immunol. Res."},{"key":"2705_CR117","doi-asserted-by":"publisher","first-page":"112732","DOI":"10.1016\/j.celrep.2023.112732","volume":"42","author":"MT Patterson","year":"2023","unstructured":"Patterson, M. T. et al. Tumor-specific CD4 T cells instruct monocyte fate in pancreatic ductal adenocarcinoma. Cell Rep. 42, 112732 (2023).","journal-title":"Cell Rep."},{"key":"2705_CR118","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/s43018-023-00521-2","volume":"4","author":"DE Speiser","year":"2023","unstructured":"Speiser, D. E., Chijioke, O., Schaeuble, K. & M\u00fcnz, C. CD4+ T cells in cancer. Nat. Cancer 4, 317\u2013329 (2023).","journal-title":"Nat. Cancer"},{"key":"2705_CR119","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1158\/1078-0432.CCR-23-1444","volume":"30","author":"LR Ali","year":"2024","unstructured":"Ali, L. R. et al. PD-1 blockade induces reactivation of Nonproductive T-cell responses characterized by NF-\u03baB Signaling In Patients With Pancreatic Cancer. Clin. Can. Res. 30, 542\u2013553 (2024).","journal-title":"Clin. Can. Res."},{"key":"2705_CR120","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1016\/j.tips.2024.10.009","volume":"45","author":"AG Weinstein","year":"2024","unstructured":"Weinstein, A. G. & DeNardo, D. G. Targeting dendritic cells to drive PDAC immunotherapy response. Trends Pharm. Sci. 45, 1095\u20131096 (2024).","journal-title":"Trends Pharm. Sci."},{"key":"2705_CR121","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1158\/2159-8290.CD-22-0876","volume":"13","author":"C Falcomat\u00e0","year":"2023","unstructured":"Falcomat\u00e0, C. et al. Context-specific determinants of the immunosuppressive tumor microenvironment in pancreatic cancer. Cancer Discov. 13, 278\u2013297 (2023).","journal-title":"Cancer Discov."},{"key":"2705_CR122","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.semcancer.2022.03.021","volume":"86","author":"R Bhatia","year":"2022","unstructured":"Bhatia, R. et al. Cytokines chattering in pancreatic ductal adenocarcinoma tumor microenvironment. Semin Cancer Biol. 86, 499\u2013510 (2022).","journal-title":"Semin Cancer Biol."},{"key":"2705_CR123","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.cytogfr.2023.06.006","volume":"71-72","author":"DS Reddy","year":"2023","unstructured":"Reddy, D. S. et al. Targeting the metabolism and immune system in pancreatic ductal adenocarcinoma: Insights and future directions. Cytokine Growth Factor Rev. 71-72, 26\u201339 (2023).","journal-title":"Cytokine Growth Factor Rev."},{"key":"2705_CR124","doi-asserted-by":"publisher","first-page":"5423","DOI":"10.1158\/1078-0432.CCR-06-0369","volume":"12","author":"N Hiraoka","year":"2006","unstructured":"Hiraoka, N., Onozato, K., Kosuge, T. & Hirohashi, S. Prevalence of FOXP3+ regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions. Clin. Cancer Res. 12, 5423\u20135434 (2006).","journal-title":"Clin. Cancer Res."},{"key":"2705_CR125","doi-asserted-by":"publisher","first-page":"1406250","DOI":"10.3389\/fimmu.2024.1406250","volume":"15","author":"H Smith","year":"2024","unstructured":"Smith, H., Arbe-Barnes, E., Shah, E. A. & Sivakumar, S. Manipulating regulatory T cells: is it the key to unlocking effective immunotherapy for pancreatic ductal adenocarcinoma?. Front. Immunol. 15, 1406250 (2024).","journal-title":"Front. Immunol."},{"key":"2705_CR126","doi-asserted-by":"publisher","unstructured":"Suzuki, K. et al. Tumor-resident regulatory T cells in pancreatic cancer express the \u03b1v\u03b25 integrin as a targetable activation marker. Preprint at https:\/\/doi.org\/10.1101\/2023.05.24.542137 (2023).","DOI":"10.1101\/2023.05.24.542137"},{"key":"2705_CR127","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-55424-2","volume":"16","author":"S Sivakumar","year":"2025","unstructured":"Sivakumar, S. et al. Distinct immune cell infiltration patterns in pancreatic ductal adenocarcinoma (PDAC) exhibit divergent immune cell selection and immunosuppressive mechanisms. Nat. Commun. 16, 1397 (2025).","journal-title":"Nat. Commun."},{"key":"2705_CR128","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1158\/1535-7163.MCT-22-0570","volume":"22","author":"Y Nagira","year":"2023","unstructured":"Nagira, Y. et al. S-531011, a novel anti-human CCR8 antibody, induces potent antitumor responses through depletion of tumor-infiltrating CCR8-expressing regulatory T cells. Mol. Cancer Ther. 22, 1063\u20131072 (2023).","journal-title":"Mol. Cancer Ther."},{"key":"2705_CR129","doi-asserted-by":"publisher","first-page":"6086","DOI":"10.1073\/pnas.1621280114","volume":"114","author":"Y Barsheshet","year":"2017","unstructured":"Barsheshet, Y. et al. CCR8(+)FOXp3(+) T(reg) cells as master drivers of immune regulation. Proc. Natl. Acad. Sci. USA 114, 6086\u20136091 (2017).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2705_CR130","doi-asserted-by":"publisher","first-page":"e2114282119","DOI":"10.1073\/pnas.2114282119","volume":"119","author":"Y Kidani","year":"2022","unstructured":"Kidani, Y. et al. CCR8-targeted specific depletion of clonally expanded Treg cells in tumor tissues evokes potent tumor immunity with long-lasting memory. Proc. Natl. Acad. Sci. USA 119, e2114282119 (2022).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2705_CR131","doi-asserted-by":"publisher","first-page":"2141007","DOI":"10.1080\/2162402X.2022.2141007","volume":"11","author":"JD Weaver","year":"2022","unstructured":"Weaver, J. D. et al. Differential expression of CCR8 in tumors versus normal tissue allows specific depletion of tumor-infiltrating T regulatory cells by GS-1811, a novel Fc-optimized anti-CCR8 antibody. Oncoimmunol 11, 2141007 (2022).","journal-title":"Oncoimmunol"},{"key":"2705_CR132","doi-asserted-by":"publisher","first-page":"102310","DOI":"10.1016\/j.jaut.2019.102310","volume":"104","author":"T Alissafi","year":"2019","unstructured":"Alissafi, T. et al. Balancing cancer immunotherapy and immune-related adverse events: the emerging role of regulatory T cells. J. Autoimmun. 104, 102310 (2019).","journal-title":"J. Autoimmun."},{"key":"2705_CR133","doi-asserted-by":"publisher","first-page":"e2023739118","DOI":"10.1073\/pnas.2023739118","volume":"118","author":"M Tekguc","year":"2021","unstructured":"Tekguc, M. et al. Treg-expressed CTLA-4 depletes CD80\/CD86 by trogocytosis, releasing free PD-L1 on antigen-presenting cells. Proc. Natl. Acad. Sci. USA 118, e2023739118 (2021).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2705_CR134","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1007\/s00262-017-2053-4","volume":"66","author":"F Bengsch","year":"2017","unstructured":"Bengsch, F. et al. CTLA-4\/CD80 pathway regulates T cell infiltration into pancreatic cancer. Cancer Immunol. Immunother. 66, 1609\u20131617 (2017).","journal-title":"Cancer Immunol. Immunother."},{"key":"2705_CR135","doi-asserted-by":"publisher","first-page":"1142838","DOI":"10.3389\/fonc.2023.1142838","volume":"13","author":"R Anu","year":"2023","unstructured":"Anu, R., Shiu, K.-K. & Khan, K. H. The immunomodulatory role of IDO1-Kynurenine-NAD+ pathway in switching cold tumor microenvironment in PDAC. Front. Oncol. 13, 1142838 (2023).","journal-title":"Front. Oncol."},{"key":"2705_CR136","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s43556-025-00300-8","volume":"6","author":"W Li","year":"2025","unstructured":"Li, W. et al. Dendritic cells: understanding ontogeny, subsets, functions, and their clinical applications. Mol. Biomed. 6, 1\u201337 (2025).","journal-title":"Mol. Biomed."},{"key":"2705_CR137","doi-asserted-by":"publisher","first-page":"217321","DOI":"10.1016\/j.canlet.2024.217321","volume":"607","author":"CS Mundry","year":"2024","unstructured":"Mundry, C. S. et al. Single-cell RNA-sequencing of human spleens reveals an IDO-1+ tolerogenic dendritic cell subset in pancreatic cancer patients that is absent in normal individuals. Cancer Lett. 607, 217321 (2024).","journal-title":"Cancer Lett."},{"key":"2705_CR138","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13046-025-03375-x","volume":"44","author":"D Masmoudi","year":"2025","unstructured":"Masmoudi, D., Villalba, M. & Alix-Panabi\u00e8res, C. Natural killer cells: the immune frontline against circulating tumor cells. J. Exp. Clin. Cancer Res. 44, 1\u201315 (2025).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"2705_CR139","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-024-01505-0","volume":"22","author":"H Cui","year":"2024","unstructured":"Cui, H. et al. The dynamic shifts of IL-10-producing Th17 and IL-17-producing Treg in health and disease: a crosstalk between ancient\u201d Yin-Yang\u201d theory and modern immunology. Cell Commun. Signal. 22, 99 (2024).","journal-title":"Cell Commun. Signal."},{"key":"2705_CR140","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1038\/s43018-022-00447-1","volume":"3","author":"I Yofe","year":"2022","unstructured":"Yofe, I. et al. Anti-CTLA-4 antibodies drive myeloid activation and reprogram the tumor microenvironment through Fc\u03b3R engagement and type I interferon signaling. Nat. Cancer 3, 1336\u20131350 (2022).","journal-title":"Nat. Cancer"},{"key":"2705_CR141","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1111\/cas.15756","volume":"114","author":"T Watanabe","year":"2023","unstructured":"Watanabe, T. et al. Activated CTLA-4-independent immunosuppression of Treg cells disturbs CTLA-4 blockade-mediated antitumor immunity. Cancer Sci. 114, 1859\u20131870 (2023).","journal-title":"Cancer Sci."},{"key":"2705_CR142","doi-asserted-by":"publisher","first-page":"e1016700","DOI":"10.1080\/2162402X.2015.1016700","volume":"4","author":"AA Wu","year":"2015","unstructured":"Wu, A. A. et al. Reprogramming the tumor microenvironment: tumor-induced immunosuppressive factors paralyze T cells. Oncoimmunol 4, e1016700 (2015).","journal-title":"Oncoimmunol"},{"key":"2705_CR143","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1136\/gutjnl-2022-327855","volume":"72","author":"FSR Picard","year":"2023","unstructured":"Picard, F. S. R. et al. IL-17A-producing CD8+ T cells promote PDAC via induction of inflammatory cancer-associated fibroblasts. Gut 72, 1510\u20131522 (2023).","journal-title":"Gut"},{"key":"2705_CR144","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/s41586-023-06063-y","volume":"618","author":"LA Rojas","year":"2023","unstructured":"Rojas, L. A. et al. Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. Nature 618, 144\u2013150 (2023).","journal-title":"Nature"},{"key":"2705_CR145","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41586-024-08508-4","volume":"639","author":"Z Sethna","year":"2025","unstructured":"Sethna, Z. et al. RNA neoantigen vaccines prime long-lived CD8+ T cells in pancreatic cancer. Nature 639, 1\u201310 (2025).","journal-title":"Nature"},{"key":"2705_CR146","doi-asserted-by":"publisher","first-page":"e010908","DOI":"10.1136\/jitc-2024-010908","volume":"13","author":"X Xing","year":"2025","unstructured":"Xing, X. et al. B4GALT5 inhibits CD8(+) T-cell response by downregulating MHC-I level through ERAD pathway in PDAC. J. Immunother. Cancer 13, e010908 (2025).","journal-title":"J. Immunother. Cancer"},{"key":"2705_CR147","doi-asserted-by":"publisher","first-page":"1845424","DOI":"10.1080\/2162402X.2020.1845424","volume":"9","author":"F Marcon","year":"2020","unstructured":"Marcon, F. et al. NK cells in pancreatic cancer demonstrate impaired cytotoxicity and a regulatory IL-10 phenotype. Oncoimmunol 9, 1845424 (2020).","journal-title":"Oncoimmunol"},{"key":"2705_CR148","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.70046","volume":"14","author":"A Zhu","year":"2024","unstructured":"Zhu, A., Bai, Y., Nan, Y. & Ju, D. Natural killer cell engagers: from bi-specific to tri-specific and tetra-specific engagers for enhanced cancer immunotherapy. Clin. Transl. Med. 14, e70046 (2024).","journal-title":"Clin. Transl. Med."},{"key":"2705_CR149","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1038\/sj.cdd.4402170","volume":"15","author":"A Moretta","year":"2008","unstructured":"Moretta, A. et al. NK cells at the interface between innate and adaptive immunity. Cell Death Diff. 15, 226\u2013233 (2008).","journal-title":"Cell Death Diff."},{"key":"2705_CR150","doi-asserted-by":"publisher","first-page":"106898","DOI":"10.1016\/j.imlet.2024.106898","volume":"269","author":"S Carlomagno","year":"2024","unstructured":"Carlomagno, S., Setti, C., Ortolani, F. & Sivori, S. Pancreatic ductal adenocarcinoma microenvironment: soluble factors and cancer associated fibroblasts as modulators of NK cell functions. Immunol. Lett. 269, 106898 (2024).","journal-title":"Immunol. Lett."},{"key":"2705_CR151","doi-asserted-by":"publisher","first-page":"515","DOI":"10.3390\/ijms26020515","volume":"26","author":"S Fanijavadi","year":"2025","unstructured":"Fanijavadi, S., Thomassen, M. & Jensen, L. H. Targeting triple NK cell suppression mechanisms: a comprehensive review of biomarkers in pancreatic cancer therapy. Int. J. Mol. Sci. 26, 515 (2025).","journal-title":"Int. J. Mol. Sci."},{"key":"2705_CR152","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-023-03134-y","volume":"23","author":"A Rahimi","year":"2023","unstructured":"Rahimi, A. et al. The nexus of natural killer cells and melanoma tumor microenvironment: crosstalk, chemotherapeutic potential, and innovative NK cell-based therapeutic strategies. Cancer Cell Int. 23, 312 (2023).","journal-title":"Cancer Cell Int."},{"key":"2705_CR153","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-15104-3","volume":"11","author":"F Demircioglu","year":"2020","unstructured":"Demircioglu, F. et al. Cancer associated fibroblast FAK regulates malignant cell metabolism. Nat. Commun. 11, 1290 (2020).","journal-title":"Nat. Commun."},{"key":"2705_CR154","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12094-024-03723-x","volume":"27","author":"LB Kwantwi","year":"2024","unstructured":"Kwantwi, L. B. & Tandoh, T. Focal adhesion kinase-mediated interaction between tumor and immune cells in the tumor microenvironment: Implications for cancer-associated therapies and tumor progression. Clin. Transl. Oncol. 27, 1\u20138 (2024).","journal-title":"Clin. Transl. Oncol."},{"key":"2705_CR155","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.cytogfr.2022.07.007","volume":"69","author":"W Zhang","year":"2023","unstructured":"Zhang, W. et al. MDSCs in sepsis-induced immunosuppression and its potential therapeutic targets. Cytokine Growth Factor Rev. 69, 90\u2013103 (2023).","journal-title":"Cytokine Growth Factor Rev."},{"key":"2705_CR156","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.cpt.2023.11.001","volume":"2","author":"P Sarangi","year":"2024","unstructured":"Sarangi, P. Role of indoleamine 2, 3-dioxygenase 1 in immunosuppression of breast cancer. Cancer Pathog. Ther. 2, 246\u2013255 (2024).","journal-title":"Cancer Pathog. Ther."},{"key":"2705_CR157","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1158\/2159-8290.CD-19-0620","volume":"10","author":"N Muthalagu","year":"2020","unstructured":"Muthalagu, N. et al. Repression of the type I interferon pathway underlies MYC-and KRAS-dependent evasion of NK and B cells in pancreatic ductal adenocarcinoma. Cancer Discov. 10, 872\u2013887 (2020).","journal-title":"Cancer Discov."},{"key":"2705_CR158","doi-asserted-by":"publisher","first-page":"1832","DOI":"10.4049\/jimmunol.1401224","volume":"194","author":"EL Briercheck","year":"2015","unstructured":"Briercheck, E. L. et al. PTEN is a negative regulator of NK cell cytolytic function. J. Immunol. 194, 1832\u20131840 (2015).","journal-title":"J. Immunol."},{"key":"2705_CR159","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1016\/j.ccell.2021.07.007","volume":"39","author":"WA Freed-Pastor","year":"2021","unstructured":"Freed-Pastor, W. A. et al. The CD155\/TIGIT axis promotes and maintains immune evasion in neoantigen-expressing pancreatic cancer. Cancer cell. 39, 1342\u20131360.e1314 (2021).","journal-title":"Cancer cell."},{"key":"2705_CR160","doi-asserted-by":"publisher","first-page":"e2012469118","DOI":"10.1073\/pnas.2012469118","volume":"118","author":"AM Moore","year":"2021","unstructured":"Moore, A. M. et al. NAD+ depletion by type I interferon signaling sensitizes pancreatic cancer cells to NAMPT inhibition. Proc. Natl. Acad. Sci. USA 118, e2012469118 (2021).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2705_CR161","doi-asserted-by":"publisher","first-page":"41","DOI":"10.3390\/epigenomes8040041","volume":"8","author":"P Liu","year":"2024","unstructured":"Liu, P., Jacques, J. & Hwang, C.-I. Epigenetic landscape of DNA methylation in pancreatic ductal adenocarcinoma. Epigenomes 8, 41 (2024).","journal-title":"Epigenomes"},{"key":"2705_CR162","doi-asserted-by":"publisher","first-page":"216462","DOI":"10.1016\/j.canlet.2023.216462","volume":"579","author":"V Kumar","year":"2023","unstructured":"Kumar, V. & Mahato, R. I. Natural killer cells for pancreatic cancer immunotherapy: role of nanoparticles. Cancer Lett. 579, 216462 (2023).","journal-title":"Cancer Lett."},{"key":"2705_CR163","doi-asserted-by":"publisher","first-page":"e179014","DOI":"10.1172\/JCI179014","volume":"135","author":"Z Dai","year":"2025","unstructured":"Dai, Z. et al. Off-the-shelf invariant NKT cells expressing anti-PSCA CAR and IL-15 promote pancreatic cancer regression in mice. J. Clin. Investig. 135, e179014 (2025).","journal-title":"J. Clin. Investig."},{"key":"2705_CR164","doi-asserted-by":"publisher","first-page":"175883592513202","DOI":"10.1177\/17588359251320280","volume":"17","author":"F Abodunrin","year":"2025","unstructured":"Abodunrin, F., Olson, D. J., Emehinola, O. & Bestvina, C. M. Adopting tomorrow\u2019s therapies today: a perspective review of adoptive cell therapy in lung cancer. Ther. Adv. Med. Oncol. 17, 17588359251320280 (2025).","journal-title":"Ther. Adv. Med. Oncol."},{"key":"2705_CR165","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/s41423-024-01145-x","volume":"21","author":"A Page","year":"2024","unstructured":"Page, A., Chuvin, N., Valladeau-Guilemond, J. & Depil, S. Development of NK cell-based cancer immunotherapies through receptor engineering. Cell Mol. Immunol. 21, 315\u2013331 (2024).","journal-title":"Cell Mol. Immunol."},{"key":"2705_CR166","doi-asserted-by":"publisher","first-page":"2406","DOI":"10.1016\/j.ymthe.2024.12.057","volume":"33","author":"H Hosseinalizadeh","year":"2025","unstructured":"Hosseinalizadeh, H. et al. Emerging combined CAR-NK cell therapies in cancer treatment: finding a dancing partner. Mol. Ther. 33, 2406\u20132425 (2025).","journal-title":"Mol. Ther."},{"key":"2705_CR167","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12964-021-00789-w","volume":"19","author":"H-B Li","year":"2021","unstructured":"Li, H.-B., Yang, Z.-H. & Guo, Q.-Q. Immune checkpoint inhibition for pancreatic ductal adenocarcinoma: limitations and prospects: a systematic review. Cell Commun. Signal. 19, 1\u201313 (2021).","journal-title":"Cell Commun. Signal."},{"key":"2705_CR168","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13046-021-01987-7","volume":"40","author":"H Zhang","year":"2021","unstructured":"Zhang, H. et al. Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer. J. Exp. Clin. Cancer Res. 40, 1\u201322 (2021).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"2705_CR169","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1038\/s41392-021-00823-w","volume":"6","author":"K Shah","year":"2021","unstructured":"Shah, K., Al-Haidari, A., Sun, J. & Kazi, J. U. T cell receptor (TCR) signaling in health and disease. Signal Transduct. Target Ther. 6, 412 (2021).","journal-title":"Signal Transduct. Target Ther."},{"key":"2705_CR170","doi-asserted-by":"publisher","first-page":"102345","DOI":"10.1016\/j.coi.2023.102345","volume":"83","author":"E Bawden","year":"2023","unstructured":"Bawden, E. & Gebhardt, T. The multifaceted roles of CD4+ T cells and MHC class II in cancer surveillance. Curr. Opin. Immunol. 83, 102345 (2023).","journal-title":"Curr. Opin. Immunol."},{"key":"2705_CR171","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1038\/s41590-023-01569-z","volume":"24","author":"V Aggarwal","year":"2023","unstructured":"Aggarwal, V., Workman, C. J. & Vignali, D. A. LAG-3 as the third checkpoint inhibitor. Nat. Immunol. 24, 1415\u20131422 (2023).","journal-title":"Nat. Immunol."},{"key":"2705_CR172","doi-asserted-by":"publisher","first-page":"1181538","DOI":"10.3389\/fendo.2023.1181538","volume":"14","author":"Y Pan","year":"2023","unstructured":"Pan, Y. et al. High-dimensional single-cell analysis unveils distinct immune signatures of peripheral blood in patients with pancreatic ductal adenocarcinoma. Front Endocrinol. 14, 1181538 (2023).","journal-title":"Front Endocrinol."},{"key":"2705_CR173","first-page":"1","volume":"55","author":"S Mishra","year":"2023","unstructured":"Mishra, S. et al. T cell exhaustion and activation markers in pancreatic cancer: a systematic review. J. Gastrointest. Cancer 55, 1\u201319 (2023).","journal-title":"J. Gastrointest. Cancer"},{"key":"2705_CR174","doi-asserted-by":"publisher","first-page":"135","DOI":"10.2217\/imt-2021-0075","volume":"15","author":"E Li","year":"2023","unstructured":"Li, E. et al. Galectin-9 and PD-L1 antibody blockade combination therapy inhibits tumour progression in pancreatic cancer. Immunotherapy 15, 135\u2013147 (2023).","journal-title":"Immunotherapy"},{"key":"2705_CR175","doi-asserted-by":"crossref","unstructured":"Das, M., Zhu, C. & Kuchroo, V. K. Tim\u20103 and its role in regulating anti\u2010tumor immunity. Immunol. Rev. 276, 97\u2013111, (2017).","DOI":"10.1111\/imr.12520"},{"key":"2705_CR176","first-page":"62","volume":"4","author":"P Gulhati","year":"2023","unstructured":"Gulhati, P. et al. Targeting T cell checkpoints 41BB and LAG3 and myeloid cell CXCR1\/CXCR2 results in antitumor immunity and durable response in pancreatic cancer. Nat. Cancer 4, 62\u201380 (2023).","journal-title":"Nat. Cancer"},{"key":"2705_CR177","doi-asserted-by":"publisher","first-page":"216366","DOI":"10.1016\/j.canlet.2023.216366","volume":"573","author":"J Wang","year":"2023","unstructured":"Wang, J. et al. Engineered TCR T-cell therapy targeting mass spectrometry-identified natural epitope in PDAC. Cancer Lett. 573, 216366 (2023).","journal-title":"Cancer Lett."},{"key":"2705_CR178","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1016\/j.ccell.2022.10.001","volume":"40","author":"K Li","year":"2022","unstructured":"Li, K. et al. Multi-omic analyses of changes in the tumor microenvironment of pancreatic adenocarcinoma following neoadjuvant treatment with anti-PD-1 therapy. Cancer Cell. 40, 1374\u20131391.e1377 (2022).","journal-title":"Cancer Cell."},{"key":"2705_CR179","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s13046-023-02935-3","volume":"43","author":"W Luo","year":"2024","unstructured":"Luo, W., Wen, T. & Qu, X. Tumor immune microenvironment-based therapies in pancreatic ductal adenocarcinoma: time to update the concept. J. Exp. Clin. Cancer Res. 43, 8 (2024).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"2705_CR180","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1038\/s41416-022-02028-6","volume":"128","author":"G Piro","year":"2023","unstructured":"Piro, G. et al. CXCR1\/2 dual-inhibitor ladarixin reduces tumour burden and promotes immunotherapy response in pancreatic cancer. Br. J. Cancer 128, 331\u2013341 (2023).","journal-title":"Br. J. Cancer"},{"key":"2705_CR181","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1038\/s43018-021-00269-7","volume":"2","author":"AR Parikh","year":"2021","unstructured":"Parikh, A. R. et al. Radiation therapy enhances immunotherapy response in microsatellite stable colorectal and pancreatic adenocarcinoma in a phase II trial. Nat. Cancer 2, 1124\u20131135 (2021).","journal-title":"Nat. Cancer"},{"key":"2705_CR182","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/s41586-025-08717-5","volume":"641","author":"Y Shen","year":"2025","unstructured":"Shen, Y. et al. Oncolytic virus VG161 in refractory hepatocellular carcinoma. Nature 641, 503\u2013511 (2025).","journal-title":"Nature"},{"key":"2705_CR183","doi-asserted-by":"publisher","first-page":"oyae323","DOI":"10.1093\/oncolo\/oyae323","volume":"30","author":"V Chung","year":"2025","unstructured":"Chung, V. et al. Pembrolizumab \u00b1 paricalcitol in metastatic pancreatic cancer postmaximal cytoreduction. Oncologist 30, oyae323 (2025).","journal-title":"Oncologist"},{"key":"2705_CR184","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1038\/s41392-024-02052-3","volume":"9","author":"L Yi","year":"2024","unstructured":"Yi, L. et al. Clinical and biomarker analyses of SHR-1701 combined with famitinib in patients with previously treated advanced biliary tract cancer or pancreatic ductal adenocarcinoma: a phase II trial. Signal Transduct. Target Ther. 9, 347 (2024).","journal-title":"Signal Transduct. Target Ther."},{"key":"2705_CR185","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s00262-024-03806-2","volume":"73","author":"J Li","year":"2024","unstructured":"Li, J. et al. SAFFRON-104: a phase Ib\/II study of sitravatinib alone or with tislelizumab in advanced hepatocellular carcinoma and gastric cancer\/gastroesophageal junction cancer. Cancer Immunol. Immunother. 73, 219 (2024).","journal-title":"Cancer Immunol. Immunother."},{"key":"2705_CR186","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s00262-024-03932-x","volume":"74","author":"Y Cheng","year":"2025","unstructured":"Cheng, Y. et al. Efficacy and safety of surufatinib plus toripalimab in treatment-naive, PD-L1-positive, advanced or metastatic non-small-cell lung cancer and previously treated small-cell lung cancer: an open-label, single-arm, multicenter, multi-cohort phase II trial. Cancer Immunol. Immunother. 74, 83 (2025).","journal-title":"Cancer Immunol. Immunother."},{"key":"2705_CR187","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1007\/s00423-025-03735-3","volume":"410","author":"FJ H\u00fcttner","year":"2025","unstructured":"H\u00fcttner, F. J. et al. Pancreatic resection with perioperative drug repurposing of propranolol and etodolac - the phase II randomized controlled PROSPER trial. Langenbecks Arch. Surg. 410, 168 (2025).","journal-title":"Langenbecks Arch. Surg."},{"key":"2705_CR188","doi-asserted-by":"publisher","first-page":"e808","DOI":"10.1634\/theoncologist.2019-0473","volume":"25","author":"SD Kamath","year":"2020","unstructured":"Kamath, S. D. et al. Ipilimumab and gemcitabine for advanced pancreatic cancer: a phase Ib study. Oncologist 25, e808\u2013e815 (2020).","journal-title":"Oncologist"},{"key":"2705_CR189","doi-asserted-by":"publisher","first-page":"3196","DOI":"10.3390\/biomedicines10123196","volume":"10","author":"L Akhuba","year":"2022","unstructured":"Akhuba, L., Tigai, Z. & Shek, D. Where do we stand with immunotherapy for advanced pancreatic ductal adenocarcinoma: a synopsis of clinical outcomes. Biomedicines 10, 3196 (2022).","journal-title":"Biomedicines"},{"key":"2705_CR190","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.2147\/CMAR.S267260","volume":"14","author":"C Kole","year":"2022","unstructured":"Kole, C. et al. Immunotherapy in combination with well-established treatment strategies in pancreatic cancer: current insights. Cancer Manag Res. 14, 1043\u20131061 (2022).","journal-title":"Cancer Manag Res."},{"key":"2705_CR191","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s13046-022-02273-w","volume":"41","author":"L Liu","year":"2022","unstructured":"Liu, L. et al. Combination therapy for pancreatic cancer: anti-PD-(L) 1-based strategy. J. Exp. Clin. Cancer Res. 41, 56 (2022).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"2705_CR192","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.ctrv.2019.06.005","volume":"78","author":"A Henriksen","year":"2019","unstructured":"Henriksen, A., Dyhl-Polk, A., Chen, I. & Nielsen, D. Checkpoint inhibitors in pancreatic cancer. Cancer Treat. Rev. 78, 17\u201330 (2019).","journal-title":"Cancer Treat. Rev."},{"key":"2705_CR193","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1080\/1744666X.2022.2120471","volume":"18","author":"GC G\u00f6ssling","year":"2022","unstructured":"G\u00f6ssling, G. C., Zhen, D. B., Pillarisetty, V. G. & Chiorean, E. G. Combination immunotherapy for pancreatic cancer: challenges and future considerations. Expert Rev. Clin. Immunol. 18, 1173\u20131186 (2022).","journal-title":"Expert Rev. Clin. Immunol."},{"key":"2705_CR194","doi-asserted-by":"publisher","first-page":"8","DOI":"10.14218\/JERP.2023.00049","volume":"9","author":"JF Murphy","year":"2024","unstructured":"Murphy, J. F. Therapeutic vaccination and cancer immunotherapy. J. Explor Res. Pharmacol. 9, 8\u201312 (2024).","journal-title":"J. Explor Res. Pharmacol."},{"key":"2705_CR195","doi-asserted-by":"publisher","first-page":"2789","DOI":"10.1200\/JCO.21.02616","volume":"40","author":"NA Ullman","year":"2022","unstructured":"Ullman, N. A., Burchard, P. R., Dunne, R. F. & Linehan, D. C. Immunologic strategies in pancreatic cancer: making cold tumors hot. J. Clin. Oncol. 40, 2789\u20132805 (2022).","journal-title":"J. Clin. Oncol."},{"key":"2705_CR196","doi-asserted-by":"publisher","first-page":"e002723","DOI":"10.1136\/jitc-2021-002723","volume":"9","author":"K Kirtane","year":"2021","unstructured":"Kirtane, K., Elmariah, H., Chung, C. H. & Abate-Daga, D. Adoptive cellular therapy in solid tumor malignancies: review of the literature and challenges ahead. J. Immunother. Cancer 9, e002723 (2021).","journal-title":"J. Immunother. Cancer"},{"key":"2705_CR197","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-021-01489-2","volume":"21","author":"M Yi","year":"2022","unstructured":"Yi, M. et al. Combination strategies with PD-1\/PD-L1 blockade: current advances and future directions. Mol. Cancer 21, 28 (2022).","journal-title":"Mol. Cancer"},{"key":"2705_CR198","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10555-021-09988-w","volume":"40","author":"CJ Herting","year":"2021","unstructured":"Herting, C. J., Karpovsky, I. & Lesinski, G. B. The tumor microenvironment in pancreatic ductal adenocarcinoma: current perspectives and future directions. Cancer Metastasis Rev. 40, 1\u201315 (2021).","journal-title":"Cancer Metastasis Rev."},{"key":"2705_CR199","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01926-4","volume":"23","author":"Y Li","year":"2024","unstructured":"Li, Y., Sharma, A. & Schmidt-Wolf, I. G. Evolving insights into the improvement of adoptive T-cell immunotherapy through PD-1\/PD-L1 blockade in the clinical spectrum of lung cancer. Mol. Cancer 23, 80 (2024).","journal-title":"Mol. Cancer"},{"key":"2705_CR200","doi-asserted-by":"publisher","first-page":"2246","DOI":"10.1172\/JCI73639","volume":"124","author":"A Gros","year":"2014","unstructured":"Gros, A. et al. PD-1 identifies the patient-specific CD8\u207a tumor-reactive repertoire infiltrating human tumors. J. Clin. Investig. 124, 2246\u20132259 (2014).","journal-title":"J. Clin. Investig."},{"key":"2705_CR201","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1038\/s41571-021-00507-y","volume":"18","author":"I Melero","year":"2021","unstructured":"Melero, I. et al. Intratumoural administration and tumour tissue targeting of cancer immunotherapies. Nat. Rev. Clin. Oncol. 18, 558\u2013576 (2021).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2705_CR202","doi-asserted-by":"publisher","first-page":"1536783","DOI":"10.3389\/fbinf.2025.1536783","volume":"5","author":"K Bhattacharjee","year":"2025","unstructured":"Bhattacharjee, K., Sengupta, A., Kumar, R. & Ghosh, A. Identification of key hub genes in pancreatic ductal adenocarcinoma: an integrative bioinformatics study. Front. Bioinform. 5, 1536783 (2025).","journal-title":"Front. Bioinform."},{"key":"2705_CR203","doi-asserted-by":"publisher","first-page":"102537","DOI":"10.1016\/j.ceb.2025.102537","volume":"95","author":"M Mil\u00e1n","year":"2025","unstructured":"Mil\u00e1n, M. Chromosomal instability in development and disease: Beyond cancer evolution. Curr. Opin. Cell Biol. 95, 102537 (2025).","journal-title":"Curr. Opin. Cell Biol."},{"key":"2705_CR204","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/s41576-024-00761-7","volume":"26","author":"X Chen","year":"2025","unstructured":"Chen, X. et al. Chromosomal instability as a driver of cancer progression. Nat. Rev. Genet. 26, 31\u201346 (2025).","journal-title":"Nat. Rev. Genet."},{"key":"2705_CR205","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1038\/s41392-023-01596-0","volume":"8","author":"L Zhong","year":"2023","unstructured":"Zhong, L., Zhao, Z. & Zhang, X. Genetic differences between primary and metastatic cancer: a pan-cancer whole-genome comparison study. Signal Transduct. Target Ther. 8, 363 (2023).","journal-title":"Signal Transduct. Target Ther."},{"key":"2705_CR206","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1158\/2159-8290.CD-22-0035","volume":"12","author":"C Johnson","year":"2022","unstructured":"Johnson, C., Burkhart, D. L. & Haigis, K. M. Classification of KRAS-Activating mutations and the implications for therapeutic intervention. Cancer Discov. 12, 913\u2013923 (2022).","journal-title":"Cancer Discov."},{"key":"2705_CR207","doi-asserted-by":"crossref","unstructured":"Jain, K. & Rana, R. in Adv Can Biomark Res (eds A. N. Singh, R. Rana, & S. Nayak) 3, 47\u201363 (Academic Press, 2025).","DOI":"10.1016\/B978-0-323-95258-3.00003-5"},{"key":"2705_CR208","doi-asserted-by":"publisher","first-page":"e103949","DOI":"10.15252\/embj.2019103949","volume":"39","author":"Y Higashijima","year":"2020","unstructured":"Higashijima, Y. et al. Coordinated demethylation of H3K9 and H3K27 is required for rapid inflammatory responses of endothelial cells. EMBO J. 39, e103949 (2020).","journal-title":"EMBO J."},{"key":"2705_CR209","doi-asserted-by":"publisher","first-page":"e292","DOI":"10.1002\/mco2.292","volume":"4","author":"R Liu","year":"2023","unstructured":"Liu, R. et al. Post-translational modifications of histones: mechanisms, biological functions, and therapeutic targets. MedComm 4, e292 (2023).","journal-title":"MedComm"},{"key":"2705_CR210","doi-asserted-by":"publisher","first-page":"eadg7112","DOI":"10.1126\/sciadv.adg7112","volume":"9","author":"Y Liu","year":"2023","unstructured":"Liu, Y. et al. FOXA1 O-GlcNAcylation\u2013mediated transcriptional switch governs metastasis capacity in breast cancer. Sci. Adv. 9, eadg7112 (2023).","journal-title":"Sci. Adv."},{"key":"2705_CR211","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1073\/pnas.94.6.2103","volume":"94","author":"PA Jones","year":"1997","unstructured":"Jones, P. A. & Gonzalgo, M. L. Altered DNA methylation and genome instability: a new pathway to cancer?. Proc. Natl. Acad. Sci. USA 94, 2103\u20132105 (1997).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2705_CR212","doi-asserted-by":"publisher","first-page":"147487","DOI":"10.1016\/j.gene.2023.147487","volume":"875","author":"A Sergeeva","year":"2023","unstructured":"Sergeeva, A., Davydova, K., Perenkov, A. & Vedunova, M. Mechanisms of human DNA methylation, alteration of methylation patterns in physiological processes and oncology. Gene 875, 147487 (2023).","journal-title":"Gene"},{"key":"2705_CR213","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1016\/j.trecan.2022.08.005","volume":"8","author":"E Espinet","year":"2022","unstructured":"Espinet, E., Klein, L., Pur\u00e9, E. & Singh, S. K. Mechanisms of PDAC subtype heterogeneity and therapy response. Trends Cancer 8, 1060\u20131071 (2022).","journal-title":"Trends Cancer"},{"key":"2705_CR214","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1080\/15384047.2021.2017223","volume":"23","author":"M Ala","year":"2022","unstructured":"Ala, M. Target c-Myc to treat pancreatic cancer. Cancer Biol. Ther. 23, 34\u201350 (2022).","journal-title":"Cancer Biol. Ther."},{"key":"2705_CR215","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1038\/s41392-024-01907-z","volume":"9","author":"S Casacuberta-Serra","year":"2024","unstructured":"Casacuberta-Serra, S., Gonz\u00e1lez-Larreategui, \u00cd, Capit\u00e1n-Leo, D. & Soucek, L. MYC and KRAS cooperation: from historical challenges to therapeutic opportunities in cancer. Signal Transduct. Target Ther. 9, 205 (2024).","journal-title":"Signal Transduct. Target Ther."},{"key":"2705_CR216","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1038\/s41392-021-00780-4","volume":"6","author":"L Huang","year":"2021","unstructured":"Huang, L., Guo, Z., Wang, F. & Fu, L. KRAS mutation: from undruggable to druggable in cancer. Signal Transduct. Target Ther. 6, 386 (2021).","journal-title":"Signal Transduct. Target Ther."},{"key":"2705_CR217","doi-asserted-by":"publisher","first-page":"12214","DOI":"10.1096\/fj.202000363RR","volume":"34","author":"N Juiz","year":"2020","unstructured":"Juiz, N. et al. Basal-like and classical cells coexist in pancreatic cancer revealed by single-cell analysis on biopsy-derived pancreatic cancer organoids from the classical subtype. FASEB J. 34, 12214\u201312228 (2020).","journal-title":"FASEB J."},{"key":"2705_CR218","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1038\/s41401-023-01194-4","volume":"45","author":"Y Chen","year":"2024","unstructured":"Chen, Y., Liu, Q. -p, Xie, H. & Ding, J. From bench to bedside: current development and emerging trend of KRAS-targeted therapy. Acta Pharm. Sin. 45, 686\u2013703 (2024).","journal-title":"Acta Pharm. Sin."},{"key":"2705_CR219","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.trecan.2024.11.009","volume":"11","author":"T Isermann","year":"2025","unstructured":"Isermann, T., Sers, C., Der, C. J. & Papke, B. KRAS inhibitors: resistance drivers and combinatorial strategies. Trends Cancer 11, 91\u2013116 (2025).","journal-title":"Trends Cancer"},{"key":"2705_CR220","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1038\/s41392-023-01705-z","volume":"8","author":"ME Bahar","year":"2023","unstructured":"Bahar, M. E., Kim, H. J. & Kim, D. R. Targeting the RAS\/RAF\/MAPK pathway for cancer therapy: from mechanism to clinical studies. Signal Transduct. Target Ther. 8, 455 (2023).","journal-title":"Signal Transduct. Target Ther."},{"key":"2705_CR221","doi-asserted-by":"publisher","first-page":"142206","DOI":"10.1016\/j.molstruc.2025.142206","volume":"1337","author":"D Kahvecioglu","year":"2025","unstructured":"Kahvecioglu, D. A comprehensive review of RAF kinase: advances in inhibition strategies for drug development. J. Mol. Struct. 1337, 142206 (2025).","journal-title":"J. Mol. Struct."},{"key":"2705_CR222","doi-asserted-by":"publisher","first-page":"206","DOI":"10.3892\/or.2023.8643","volume":"50","author":"J Zhang","year":"2023","unstructured":"Zhang, J. et al. Targeting KRAS for the potential treatment of pancreatic ductal adenocarcinoma: recent advancements provide hope (Review). Oncol. Rep. 50, 206 (2023).","journal-title":"Oncol. Rep."},{"key":"2705_CR223","doi-asserted-by":"publisher","first-page":"13193","DOI":"10.3390\/ijms222413193","volume":"22","author":"M Haidar","year":"2021","unstructured":"Haidar, M. & Jacquemin, P. Past and future strategies to inhibit membrane localization of the KRAS oncogene. Int. J. Mol. Sci. 22, 13193 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"2705_CR224","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.semcancer.2017.10.010","volume":"56","author":"SG Klochkov","year":"2019","unstructured":"Klochkov, S. G. et al. Implications of farnesyltransferase and its inhibitors as a promising strategy for cancer therapy. Semin Cancer Biol. 56, 128\u2013134 (2019).","journal-title":"Semin Cancer Biol."},{"key":"2705_CR225","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-024-02216-3","volume":"24","author":"Y Shi","year":"2025","unstructured":"Shi, Y. et al. Targeting KRAS: from metabolic regulation to cancer treatment. Mol. Cancer 24, 9 (2025).","journal-title":"Mol. Cancer"},{"key":"2705_CR226","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-36128-5","volume":"14","author":"J Liu","year":"2023","unstructured":"Liu, J. et al. Glycolysis regulates KRAS plasma membrane localization and function through defined glycosphingolipids. Nat. Commun. 14, 465 (2023).","journal-title":"Nat. Commun."},{"key":"2705_CR227","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1016\/j.cell.2012.01.058","volume":"149","author":"H Ying","year":"2012","unstructured":"Ying, H. et al. Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell 149, 656\u2013670 (2012).","journal-title":"Cell"},{"key":"2705_CR228","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1007\/s12029-024-01149-w","volume":"56","author":"T Hoang","year":"2025","unstructured":"Hoang, T. & Tsang, E. S. Advances in novel targeted therapies for pancreatic adenocarcinoma. J. Gastrointest. Cancer 56, 38 (2025).","journal-title":"J. Gastrointest. Cancer"},{"key":"2705_CR229","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1158\/0008-5472.CAN-22-0391","volume":"83","author":"CM Goodwin","year":"2023","unstructured":"Goodwin, C. M. et al. Combination therapies with CDK4\/6 inhibitors to treat KRAS-mutant pancreatic cancer. Cancer Res. 83, 141\u2013157 (2023).","journal-title":"Cancer Res."},{"key":"2705_CR230","doi-asserted-by":"publisher","first-page":"100585","DOI":"10.1016\/j.modpat.2024.100585","volume":"37","author":"A Yavas","year":"2024","unstructured":"Yavas, A. et al. SWI\/SNF complex-deficient undifferentiated carcinoma of the pancreas: clinicopathologic and genomic analysis. Mod. Pathol. 37, 100585 (2024).","journal-title":"Mod. Pathol."},{"key":"2705_CR231","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-07004-x","volume":"12","author":"S Amintas","year":"2022","unstructured":"Amintas, S. et al. KRAS gene mutation quantification in the resection or venous margins of pancreatic ductal adenocarcinoma is not predictive of disease recurrence. Sci. Rep. 12, 2976 (2022).","journal-title":"Sci. Rep."},{"key":"2705_CR232","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-60808-z","volume":"16","author":"JJ Knox","year":"2025","unstructured":"Knox, J. J. et al. Whole genome and transcriptome profiling in advanced pancreatic cancer patients on the COMPASS trial. Nat. Commun. 16, 5919 (2025).","journal-title":"Nat. Commun."},{"key":"2705_CR233","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-32591-8","volume":"13","author":"DJ Renouf","year":"2022","unstructured":"Renouf, D. J. et al. The CCTG PA.7 phase II trial of gemcitabine and nab-paclitaxel with or without durvalumab and tremelimumab as initial therapy in metastatic pancreatic ductal adenocarcinoma. Nat. Commun. 13, 5020 (2022).","journal-title":"Nat. Commun."},{"key":"2705_CR234","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1159\/000536552","volume":"17","author":"J Mody","year":"2024","unstructured":"Mody, J. & Kamgar, M. Pancreatic adenocarcinoma with Co-occurrence of KRAS and EGFR mutations: case report and literature review. Case Rep. Oncol. 17, 399\u2013406 (2024).","journal-title":"Case Rep. Oncol."},{"key":"2705_CR235","doi-asserted-by":"publisher","first-page":"e1363","DOI":"10.1002\/cti2.1363","volume":"11","author":"M van Duijvenvoorde","year":"2022","unstructured":"van Duijvenvoorde, M. et al. Comparison of the tumor microenvironments of squamous cell carcinoma at different anatomical locations within the upper aerodigestive tract in relation to response to ICI therapy. Clin. Transl. Immunol. 11, e1363 (2022).","journal-title":"Clin. Transl. Immunol."},{"key":"2705_CR236","doi-asserted-by":"publisher","first-page":"10","DOI":"10.6004\/jnccn.2020.7641","volume":"19","author":"M Gupta","year":"2021","unstructured":"Gupta, M. et al. Targeting the NTRK fusion gene in pancreatic acinar cell carcinoma: a case report and review of the literature. J. Natl. Compr. Cancer Netw. 19, 10\u201315 (2021).","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"2705_CR237","doi-asserted-by":"publisher","first-page":"115197","DOI":"10.1016\/j.ejca.2024.115197","volume":"216","author":"J Lena","year":"2025","unstructured":"Lena, J. et al. Extensive molecular profiling of KRAS wild-type as compared to KRAS mutated pancreatic ductal adenocarcinoma on 318 patients. Eur. J. Cancer 216, 115197 (2025).","journal-title":"Eur. J. Cancer"},{"key":"2705_CR238","first-page":"e87044","volume":"17","author":"CE Bonilla","year":"2025","unstructured":"Bonilla, C. E. et al. Exceptional response to multimodal therapy in stage IV pancreatic ductal adenocarcinoma: a case report and review. Cureus 17, e87044 (2025).","journal-title":"Cureus"},{"key":"2705_CR239","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.tcb.2024.06.008","volume":"35","author":"V Kalamara","year":"2025","unstructured":"Kalamara, V. & Garinis, G. A. The epitranscriptome: reshaping the DNA damage response. Trends Cell Biol. 35, 294\u2013304 (2025).","journal-title":"Trends Cell Biol."},{"key":"2705_CR240","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1080\/15384101.2019.1618542","volume":"18","author":"RD Jachimowicz","year":"2019","unstructured":"Jachimowicz, R. D., Goergens, J. & Reinhardt, H. C. DNA double-strand break repair pathway choice - from basic biology to clinical exploitation. Cell Cycle 18, 1423\u20131434 (2019).","journal-title":"Cell Cycle"},{"key":"2705_CR241","doi-asserted-by":"publisher","first-page":"723847","DOI":"10.3389\/fgene.2021.723847","volume":"12","author":"A Elbakry","year":"2021","unstructured":"Elbakry, A. & L\u00f6brich, M. Homologous recombination subpathways: a tangle to resolve. Front. Genet. 12, 723847 (2021).","journal-title":"Front. Genet."},{"key":"2705_CR242","doi-asserted-by":"publisher","first-page":"103873","DOI":"10.1016\/j.dnarep.2025.103873","volume":"152","author":"R Ortega","year":"2025","unstructured":"Ortega, R., Bitler, B. G. & Arnoult, N. Multiple functions of PARP1 in the repair of DNA double strand breaks. DNA Repair. 152, 103873 (2025).","journal-title":"DNA Repair."},{"key":"2705_CR243","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s00018-019-03366-0","volume":"77","author":"T Eisemann","year":"2020","unstructured":"Eisemann, T. & Pascal, J. M. Poly(ADP-ribose) polymerase enzymes and the maintenance of genome integrity. Cell Mol. Life Sci. 77, 19\u201333 (2020).","journal-title":"Cell Mol. Life Sci."},{"key":"2705_CR244","doi-asserted-by":"publisher","first-page":"105397","DOI":"10.1016\/j.jbc.2023.105397","volume":"299","author":"\u00c9 Rouleau-Turcotte","year":"2023","unstructured":"Rouleau-Turcotte, \u00c9 & Pascal, J. M. ADP-ribose contributions to genome stability and PARP enzyme trapping on sites of DNA damage; paradigm shifts for a coming-of-age modification. J. Biol. Chem. 299, 105397 (2023).","journal-title":"J. Biol. Chem."},{"key":"2705_CR245","doi-asserted-by":"publisher","first-page":"100950","DOI":"10.1016\/j.molmet.2020.01.014","volume":"38","author":"S Hurtado-Bag\u00e8s","year":"2020","unstructured":"Hurtado-Bag\u00e8s, S., Knobloch, G., Ladurner, A. G. & Buschbeck, M. The taming of PARP1 and its impact on NAD(+) metabolism. Mol. Metab. 38, 100950 (2020).","journal-title":"Mol. Metab."},{"key":"2705_CR246","doi-asserted-by":"publisher","first-page":"813457","DOI":"10.3389\/fcell.2022.813457","volume":"10","author":"X Fu","year":"2022","unstructured":"Fu, X. et al. BRCA1 and breast cancer: molecular mechanisms and therapeutic strategies. Front. Cell Dev. Biol. 10, 813457 (2022).","journal-title":"Front. Cell Dev. Biol."},{"key":"2705_CR247","doi-asserted-by":"publisher","DOI":"10.1177\/17562848211014818","volume":"14","author":"J Chi","year":"2021","unstructured":"Chi, J. et al. The role of PARP inhibitors in BRCA mutated pancreatic cancer. Ther. Adv. Gastroenterol. 14, 17562848211014818 (2021).","journal-title":"Ther. Adv. Gastroenterol."},{"key":"2705_CR248","doi-asserted-by":"publisher","first-page":"125028","DOI":"10.1016\/j.ijpharm.2024.125028","volume":"669","author":"R Wang","year":"2025","unstructured":"Wang, R. et al. Combating tumor PARP inhibitor resistance: Combination treatments, nanotechnology, and other potential strategies. Int. J. Pharm. 669, 125028 (2025).","journal-title":"Int. J. Pharm."},{"key":"2705_CR249","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/s41392-020-0150-x","volume":"5","author":"R-X Huang","year":"2020","unstructured":"Huang, R.-X. & Zhou, P.-K. DNA damage response signaling pathways and targets for radiotherapy sensitization in cancer. Signal Transduct. Target Ther. 5, 60 (2020).","journal-title":"Signal Transduct. Target Ther."},{"key":"2705_CR250","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1139\/O07-069","volume":"85","author":"RS Williams","year":"2007","unstructured":"Williams, R. S., Williams, J. S. & Tainer, J. A. Mre11-Rad50-Nbs1 is a keystone complex connecting DNA repair machinery, double-strand break signaling, and the chromatin template. Biochem. Cell Biol. 85, 509\u2013520 (2007).","journal-title":"Biochem. Cell Biol."},{"key":"2705_CR251","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-30303-w","volume":"13","author":"Y-L Wang","year":"2022","unstructured":"Wang, Y.-L. et al. MRNIP condensates promote DNA double-strand break sensing and end resection. Nat. Commun. 13, 2638 (2022).","journal-title":"Nat. Commun."},{"key":"2705_CR252","doi-asserted-by":"publisher","first-page":"114820","DOI":"10.1016\/j.celrep.2024.114820","volume":"43","author":"F Meng","year":"2024","unstructured":"Meng, F. et al. Base-excision repair pathway regulates transcription-replication conflicts in pancreatic ductal adenocarcinoma. Cell Rep. 43, 114820 (2024).","journal-title":"Cell Rep."},{"key":"2705_CR253","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.radonc.2017.09.043","volume":"126","author":"Z Qiu","year":"2018","unstructured":"Qiu, Z., Oleinick, N. L. & Zhang, J. ATR\/CHK1 inhibitors and cancer therapy. Radiother. Oncol. 126, 450\u2013464 (2018).","journal-title":"Radiother. Oncol."},{"key":"2705_CR254","doi-asserted-by":"publisher","first-page":"189185","DOI":"10.1016\/j.bbcan.2024.189185","volume":"1879","author":"F Moosavi","year":"2024","unstructured":"Moosavi, F. et al. Targeting DNA damage response in pancreatic ductal adenocarcinoma: a review of preclinical and clinical evidence. Biochim. Biophys. Acta Rev. Cancer 1879, 189185 (2024).","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"2705_CR255","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1080\/14728222.2025.2507035","volume":"29","author":"A Shah","year":"2025","unstructured":"Shah, A., Johnson, E., Ponnusamy, M. P. & Batra, S. K. Emerging pathways yielding opportunities for future treatments in pancreatic ductal adenocarcinoma. Expert Opin. Ther. Targets 29, 309\u2013326 (2025).","journal-title":"Expert Opin. Ther. Targets"},{"key":"2705_CR256","doi-asserted-by":"crossref","unstructured":"Godet, I. & Gilkes, D. M. BRCA1 and BRCA2 mutations and treatment strategies for breast cancer. Integr. Cancer Sci. Ther. 4, 10\u201315761 (2017).","DOI":"10.15761\/ICST.1000228"},{"key":"2705_CR257","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1001\/jamaoncol.2021.0006","volume":"7","author":"M Javle","year":"2021","unstructured":"Javle, M. et al. Olaparib monotherapy for previously treated pancreatic cancer with DNA damage repair genetic alterations other than germline BRCA variants: findings from 2 phase 2 nonrandomized clinical trials. JAMA Oncol. 7, 693\u2013699 (2021).","journal-title":"JAMA Oncol."},{"key":"2705_CR258","first-page":"272","volume":"23","author":"A Hernando-Calvo","year":"2024","unstructured":"Hernando-Calvo, A. et al. A phase II, open-label, randomized trial of Durvalumab With Olaparib or Cediranib in patients with mismatch repair-proficient colorectal or pancreatic cancer. Clin. Colorectal Cancer 23, 272\u2013284.e279 (2024).","journal-title":"Clin. Colorectal Cancer"},{"key":"2705_CR259","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1007\/s12029-025-01237-5","volume":"56","author":"K Zhao","year":"2025","unstructured":"Zhao, K. et al. Neoadjuvant Pembrolizumab enables successful downstaging and resection of borderline resectable MSI-H\/dMMR pancreatic ductal adenocarcinoma: a case report and literature review. J. Gastrointest. Cancer 56, 112 (2025).","journal-title":"J. Gastrointest. Cancer"},{"key":"2705_CR260","doi-asserted-by":"publisher","first-page":"5092","DOI":"10.1158\/1078-0432.CCR-20-1301","volume":"26","author":"MJ Pishvaian","year":"2020","unstructured":"Pishvaian, M. J. et al. A phase I\/II study of Veliparib (ABT-888) in combination with 5-fluorouracil and oxaliplatin in patients with metastatic pancreatic cancer. Clin. Cancer Res. 26, 5092\u20135101 (2020).","journal-title":"Clin. Cancer Res."},{"key":"2705_CR261","doi-asserted-by":"crossref","unstructured":"Yakushina, V. et al. Microsatellite instability detection: the current standards, limitations, and misinterpretations. JCO Precis. Oncol. 7, e2300010, (2023).","DOI":"10.1200\/PO.23.00010"},{"key":"2705_CR262","doi-asserted-by":"publisher","first-page":"2827","DOI":"10.3390\/cimb46040177","volume":"46","author":"D Stefanoudakis","year":"2024","unstructured":"Stefanoudakis, D. et al. Significance of TP53, CDKN2A, SMAD4 and KRAS in pancreatic cancer. Curr. Issues Mol. Biol. 46, 2827\u20132844 (2024).","journal-title":"Curr. Issues Mol. Biol."},{"key":"2705_CR263","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s12929-022-00856-5","volume":"29","author":"J Mandal","year":"2022","unstructured":"Mandal, J., Mandal, P., Wang, T.-L. & Shih, I.-M. Treating ARID1A mutated cancers by harnessing synthetic lethality and DNA damage response. J. Biomed. Sci. 29, 71 (2022).","journal-title":"J. Biomed. Sci."},{"key":"2705_CR264","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1016\/j.tig.2020.07.011","volume":"36","author":"RC Centore","year":"2020","unstructured":"Centore, R. C. et al. Mammalian SWI\/SNF chromatin remodeling complexes: emerging mechanisms and therapeutic strategies. Trends Genet. 36, 936\u2013950 (2020).","journal-title":"Trends Genet."},{"key":"2705_CR265","doi-asserted-by":"publisher","first-page":"1495221","DOI":"10.3389\/fimmu.2024.1495221","volume":"15","author":"X Duan","year":"2024","unstructured":"Duan, X. et al. The role of histone post-translational modifications in cancer and cancer immunity: functions, mechanisms and therapeutic implications. Front. Immunol. 15, 1495221 (2024).","journal-title":"Front. Immunol."},{"key":"2705_CR266","doi-asserted-by":"publisher","first-page":"5310","DOI":"10.1038\/sj.onc.1210599","volume":"26","author":"XJ Yang","year":"2007","unstructured":"Yang, X. J. & Seto, E. HATs and HDACs: from structure, function and regulation to novel strategies for therapy and prevention. Oncogene 26, 5310\u20135318 (2007).","journal-title":"Oncogene"},{"key":"2705_CR267","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1038\/s41392-025-02340-6","volume":"10","author":"C Galassi","year":"2025","unstructured":"Galassi, C. et al. Epigenetic regulation of cancer stemness. Signal Transduct. Target Ther. 10, 243 (2025).","journal-title":"Signal Transduct. Target Ther."},{"key":"2705_CR268","doi-asserted-by":"publisher","first-page":"2166","DOI":"10.1016\/j.molcel.2021.03.008","volume":"81","author":"T Narita","year":"2021","unstructured":"Narita, T. et al. Enhancers are activated by p300\/CBP activity-dependent PIC assembly, RNAPII recruitment, and pause release. Mol. Cell. 81, 2166\u20132182.e2166 (2021).","journal-title":"Mol. Cell."},{"key":"2705_CR269","doi-asserted-by":"publisher","first-page":"101090","DOI":"10.1016\/j.tranon.2021.101090","volume":"14","author":"M Mortoglou","year":"2021","unstructured":"Mortoglou, M. et al. Non-coding RNAs in pancreatic ductal adenocarcinoma: new approaches for better diagnosis and therapy. Transl. Oncol. 14, 101090 (2021).","journal-title":"Transl. Oncol."},{"key":"2705_CR270","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1016\/j.ejca.2015.04.006","volume":"51","author":"AE Frampton","year":"2015","unstructured":"Frampton, A. E. et al. microRNAs with prognostic significance in pancreatic ductal adenocarcinoma: a meta-analysis. Eur. J. Cancer 51, 1389\u20131404 (2015).","journal-title":"Eur. J. Cancer"},{"key":"2705_CR271","first-page":"29","volume":"10","author":"G Girolimetti","year":"2024","unstructured":"Girolimetti, G. et al. Dysregulation of a subset of circulating and vesicle-associated miRNA in pancreatic cancer. Noncoding RNA 10, 29 (2024).","journal-title":"Noncoding RNA"},{"key":"2705_CR272","doi-asserted-by":"publisher","first-page":"3967","DOI":"10.7150\/thno.40566","volume":"10","author":"Q Meng","year":"2020","unstructured":"Meng, Q. et al. A miR-146a-5p\/TRAF6\/NF-kB p65 axis regulates pancreatic cancer chemoresistance: functional validation and clinical significance. Theranostics 10, 3967\u20133979 (2020).","journal-title":"Theranostics"},{"key":"2705_CR273","doi-asserted-by":"publisher","first-page":"BSR20203559","DOI":"10.1042\/BSR20203559","volume":"41","author":"M Xiong","year":"2021","unstructured":"Xiong, M. et al. The diagnostic and prognostic values of microRNA-196a in cancer. Biosci. Rep. 41, BSR20203559 (2021).","journal-title":"Biosci. Rep."},{"key":"2705_CR274","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1186\/s13046-024-03090-z","volume":"43","author":"DSK Liu","year":"2024","unstructured":"Liu, D. S. K. et al. Unlocking the diagnostic power of plasma extracellular vesicle miR-200 family in pancreatic ductal adenocarcinoma. J. Exp. Clin. Cancer Res. 43, 189 (2024).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"2705_CR275","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1016\/j.omtn.2022.02.005","volume":"27","author":"MT Di Martino","year":"2022","unstructured":"Di Martino, M. T. et al. miR-221\/222 as biomarkers and targets for therapeutic intervention on cancer and other diseases: a systematic review. Mol. Ther. Nucleic Acids 27, 1191\u20131224 (2022).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"2705_CR276","doi-asserted-by":"publisher","DOI":"10.1002\/deo2.333","volume":"4","author":"T Taniguchi","year":"2024","unstructured":"Taniguchi, T. et al. MicroRNA-20a in extracellular vesicles derived from duodenal fluid is a possible biomarker for pancreatic ductal adenocarcinoma. DEN Open. 4, e333 (2024).","journal-title":"DEN Open."},{"key":"2705_CR277","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-018-0628-4","volume":"9","author":"JD Godfrey","year":"2018","unstructured":"Godfrey, J. D. et al. MiR-142-3p is downregulated in aggressive p53 mutant mouse models of pancreatic ductal adenocarcinoma by hypermethylation of its locus. Cell Death Dis. 9, 644 (2018).","journal-title":"Cell Death Dis."},{"key":"2705_CR278","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1159\/000447302","volume":"84","author":"LM Long","year":"2017","unstructured":"Long, L. M. et al. The clinical significance of miR-34a in Pancreatic Ductal Carcinoma And Associated Molecular And Cellular Mechanisms. Pathobiol 84, 38\u201348 (2017).","journal-title":"Pathobiol"},{"key":"2705_CR279","doi-asserted-by":"publisher","DOI":"10.1038\/s41389-019-0177-4","volume":"8","author":"NS Sharma","year":"2019","unstructured":"Sharma, N. S. et al. Long non-coding RNA GAS5 acts as proliferation \u201cbrakes\u201d in CD133+ cells responsible for tumor recurrence. Oncogenesis 8, 68 (2019).","journal-title":"Oncogenesis"},{"key":"2705_CR280","doi-asserted-by":"publisher","first-page":"620859","DOI":"10.3389\/fgene.2021.620859","volume":"12","author":"KV Good","year":"2021","unstructured":"Good, K. V., Vincent, J. B. & Ausi\u00f3, J. MeCP2: the genetic driver of rett syndrome epigenetics. Front. Genet. 12, 620859 (2021).","journal-title":"Front. Genet."},{"key":"2705_CR281","doi-asserted-by":"publisher","first-page":"48","DOI":"10.59566\/IJBS.2017.13048","volume":"13","author":"H Dana","year":"2017","unstructured":"Dana, H. et al. Molecular mechanisms and biological functions of siRNA. Int J. Biomed. Sci. 13, 48\u201357 (2017).","journal-title":"Int J. Biomed. Sci."},{"key":"2705_CR282","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.3748\/wjg.v26.i15.1745","volume":"26","author":"T Xu","year":"2020","unstructured":"Xu, T. et al. DNAH17-AS1 promotes pancreatic carcinoma by increasing PPME1 expression via inhibition of miR-432-5p. World J. Gastroenterol. 26, 1745\u20131757 (2020).","journal-title":"World J. Gastroenterol."},{"key":"2705_CR283","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-025-03775-9","volume":"15","author":"C Zhuo","year":"2025","unstructured":"Zhuo, C. et al. Computational biological analysis reveals that HIF-1 and FoxO signaling pathways influence cognitive impairment in patients with depression. Transl. Psychiatry 15, 518 (2025).","journal-title":"Transl. Psychiatry"},{"key":"2705_CR284","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1245\/s10434-019-07927-2","volume":"27","author":"M Kubo","year":"2020","unstructured":"Kubo, M. et al. Impact of CD36 on chemoresistance in pancreatic ductal adenocarcinoma. Ann. Surg. Oncol. 27, 610\u2013619 (2020).","journal-title":"Ann. Surg. Oncol."},{"key":"2705_CR285","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/sj.bjc.6602687","volume":"93","author":"A Ko","year":"2005","unstructured":"Ko, A. et al. Serum CA19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic cancer. Br. J. Cancer 93, 195\u2013199 (2005).","journal-title":"Br. J. Cancer"},{"key":"2705_CR286","doi-asserted-by":"publisher","first-page":"65","DOI":"10.3892\/or.2020.7832","volume":"45","author":"L Wang","year":"2021","unstructured":"Wang, L., Mu, N. & Qu, N. Methylation of the miR\u201129b\u20113p promoter contributes to angiogenesis, invasion, and migration in pancreatic cancer. Oncol. Rep. 45, 65\u201372 (2021).","journal-title":"Oncol. Rep."},{"key":"2705_CR287","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1038\/s41392-024-01885-2","volume":"9","author":"X Shi","year":"2024","unstructured":"Shi, X. et al. Mechanism insights and therapeutic intervention of tumor metastasis: latest developments and perspectives. Signal Transduct. Target Ther. 9, 192 (2024).","journal-title":"Signal Transduct. Target Ther."},{"key":"2705_CR288","doi-asserted-by":"publisher","first-page":"194","DOI":"10.5483\/BMBRep.2017.50.4.040","volume":"50","author":"A Yamashita","year":"2017","unstructured":"Yamashita, A. & Takeuchi, O. Translational control of mRNAs by 3\u2019-Untranslated region binding proteins. BMB Rep. 50, 194\u2013200 (2017).","journal-title":"BMB Rep."},{"key":"2705_CR289","doi-asserted-by":"publisher","first-page":"101937","DOI":"10.1016\/j.isci.2020.101937","volume":"24","author":"KM Scullion","year":"2021","unstructured":"Scullion, K. M. et al. Circulating argonaute-bound microRNA-126 reports vascular dysfunction and treatment response in acute and chronic kidney disease. iScience 24, 101937 (2021).","journal-title":"iScience"},{"key":"2705_CR290","doi-asserted-by":"publisher","first-page":"217245","DOI":"10.1016\/j.canlet.2024.217245","volume":"604","author":"B Haab","year":"2024","unstructured":"Haab, B. et al. A rigorous multi-laboratory study of known PDAC biomarkers identifies increased sensitivity and specificity over CA19-9 alone. Cancer Lett. 604, 217245 (2024).","journal-title":"Cancer Lett."},{"key":"2705_CR291","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.1038\/s41388-024-03076-3","volume":"43","author":"GAD Metcalf","year":"2024","unstructured":"Metcalf, G. A. D. MicroRNAs: circulating biomarkers for the early detection of imperceptible cancers via biosensor and machine-learning advances. Oncogene 43, 2135\u20132142 (2024).","journal-title":"Oncogene"},{"key":"2705_CR292","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s12957-025-03732-2","volume":"23","author":"M Prasad","year":"2025","unstructured":"Prasad, M., Hamsa, D., Fareed, M. & Karobari, M. I. An update on the molecular mechanisms underlying the progression of miR-21 in oral cancer. World J. Surg. Oncol. 23, 73 (2025).","journal-title":"World J. Surg. Oncol."},{"key":"2705_CR293","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-022-05103-1","volume":"13","author":"C Chen","year":"2022","unstructured":"Chen, C. et al. Gemcitabine resistance of pancreatic cancer cells is mediated by IGF1R dependent upregulation of CD44 expression and isoform switching. Cell Death Dis. 13, 682 (2022).","journal-title":"Cell Death Dis."},{"key":"2705_CR294","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-023-02138-y","volume":"40","author":"S Kannampuzha","year":"2023","unstructured":"Kannampuzha, S. & Gopalakrishnan, A. V. Cancer chemoresistance and its mechanisms: associated molecular factors and its regulatory role. Med. Oncol. 40, 264 (2023).","journal-title":"Med. Oncol."},{"key":"2705_CR295","doi-asserted-by":"publisher","first-page":"24730","DOI":"10.1021\/acs.jmedchem.5c01162","volume":"68","author":"H Li","year":"2025","unstructured":"Li, H. et al. Targeting Non-BET bromodomains: emerging opportunities in drug discovery. J. Med. Chem. 68, 24730\u201324758 (2025).","journal-title":"J. Med. Chem."},{"key":"2705_CR296","doi-asserted-by":"publisher","first-page":"101353","DOI":"10.1016\/j.gendis.2024.101353","volume":"12","author":"M Ma","year":"2025","unstructured":"Ma, M., An, J., Jiang, T. & Xie, K. GATA6 in pancreatic cancer initiation and progression. Genes Dis. 12, 101353 (2025).","journal-title":"Genes Dis."},{"key":"2705_CR297","doi-asserted-by":"publisher","first-page":"e303","DOI":"10.1097\/MPA.0000000000002431","volume":"54","author":"E Zhou","year":"2025","unstructured":"Zhou, E. et al. GATA6 amplification is associated with improved survival in TP53-mutated unresectable pancreatic cancer. Pancreas 54, e303\u2013e309 (2025).","journal-title":"Pancreas"},{"key":"2705_CR298","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1136\/gutjnl-2020-321397","volume":"71","author":"B Kloesch","year":"2022","unstructured":"Kloesch, B. et al. A GATA6-centred gene regulatory network involving HNFs and \u0394Np63 controls plasticity and immune escape in pancreatic cancer. Gut 71, 766\u2013777 (2022).","journal-title":"Gut"},{"key":"2705_CR299","doi-asserted-by":"publisher","first-page":"3058","DOI":"10.3390\/biomedicines11113058","volume":"11","author":"JD Greendyk","year":"2023","unstructured":"Greendyk, J. D. et al. Association between SMAD4 mutations and GATA6 expression in paired pancreatic ductal adenocarcinoma tumor specimens: data from two independent molecularly-characterized cohorts. Biomedicines 11, 3058 (2023).","journal-title":"Biomedicines"},{"key":"2705_CR300","doi-asserted-by":"publisher","first-page":"e23638","DOI":"10.1002\/jbt.23638","volume":"38","author":"SS Giri","year":"2024","unstructured":"Giri, S. S., Tripathi, A. S., Erkeko\u011flu, P. & Zaki, M. E. Molecular pathway of pancreatic cancer-associated neuropathic pain. J. Biochem. Mol. Toxicol. 38, e23638 (2024).","journal-title":"J. Biochem. Mol. Toxicol."},{"key":"2705_CR301","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1038\/s41388-018-0458-y","volume":"38","author":"S Na\u2019ara","year":"2019","unstructured":"Na\u2019ara, S., Amit, M. & Gil, Z. L1CAM induces perineural invasion of pancreas cancer cells by upregulation of metalloproteinase expression. Oncogene 38, 596\u2013608 (2019).","journal-title":"Oncogene"},{"key":"2705_CR302","doi-asserted-by":"publisher","first-page":"177218","DOI":"10.1016\/j.ejphar.2024.177218","volume":"988","author":"VK Deb","year":"2025","unstructured":"Deb, V. K., Chauhan, N. & Jain, U. Deciphering TGF-\u03b21\u2019s role in drug resistance and leveraging plant bioactives for cancer therapy. Eur. J. Pharmacol. 988, 177218 (2025).","journal-title":"Eur. J. Pharmacol."},{"key":"2705_CR303","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1016\/j.molonc.2014.03.001","volume":"8","author":"E Grage-Griebenow","year":"2014","unstructured":"Grage-Griebenow, E. et al. L1CAM promotes enrichment of immunosuppressive T cells in human pancreatic cancer correlating with malignant progression. Mol. Oncol. 8, 982\u2013997 (2014).","journal-title":"Mol. Oncol."},{"key":"2705_CR304","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1038\/s41392-022-01190-w","volume":"7","author":"Z-N Lei","year":"2022","unstructured":"Lei, Z.-N. et al. Signaling pathways and therapeutic interventions in gastric cancer. Signal Transduct. Target Ther. 7, 358 (2022).","journal-title":"Signal Transduct. Target Ther."},{"key":"2705_CR305","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1007\/s12668-025-01933-3","volume":"15","author":"D Singh","year":"2025","unstructured":"Singh, D. Synergistic inhibition of KRAS-driven pancreatic cancer using siRNA-loaded nanoparticles with erlotinib: a comprehensive in vitro investigation. BioNanoSci 15, 343 (2025).","journal-title":"BioNanoSci"},{"key":"2705_CR306","doi-asserted-by":"publisher","first-page":"4511","DOI":"10.3748\/wjg.v19.i28.4511","volume":"19","author":"V Vaccaro","year":"2013","unstructured":"Vaccaro, V. et al. First-line erlotinib and fixed dose-rate gemcitabine for advanced pancreatic cancer. World J. Gastroenterol. 19, 4511\u20134519 (2013).","journal-title":"World J. Gastroenterol."},{"key":"2705_CR307","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.3389\/fonc.2020.01249","volume":"10","author":"WQ Cai","year":"2020","unstructured":"Cai, W. Q. et al. The latest battles between EGFR monoclonal antibodies and resistant tumor cells. Front. Oncol. 10, 1249 (2020).","journal-title":"Front. Oncol."},{"key":"2705_CR308","first-page":"15","volume":"34","author":"J Liermann","year":"2022","unstructured":"Liermann, J. et al. Cetuximab, gemcitabine and radiotherapy in locally advanced pancreatic cancer: long-term results of the randomized controlled phase II PARC trial. Clin. Transl. Oncol. 34, 15\u201322 (2022).","journal-title":"Clin. Transl. Oncol."},{"key":"2705_CR309","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.7107","volume":"13","author":"H Arai","year":"2024","unstructured":"Arai, H. et al. Switching from FOLFIRI plus cetuximab to FOLFIRI plus bevacizumab based on early tumor shrinkage in RAS wild-type metastatic colorectal cancer: a phase II trial (HYBRID). Cancer Med. 13, e7107 (2024).","journal-title":"Cancer Med."},{"key":"2705_CR310","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1007\/s00423-022-02434-7","volume":"407","author":"M Matsumura","year":"2022","unstructured":"Matsumura, M. et al. A randomized controlled trial of surgery and postoperative modified FOLFOX6 versus surgery and perioperative modified FOLFOX6 plus cetuximab in patients with KRAS wild-type resectable colorectal liver metastases: EXPERT study. Langenbecks Arch. Surg. 407, 1345\u20131356 (2022).","journal-title":"Langenbecks Arch. Surg."},{"key":"2705_CR311","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.21037\/jgo-22-327","volume":"13","author":"SM Sanghvi","year":"2022","unstructured":"Sanghvi, S. M. et al. A phase II trial of gemcitabine and erlotinib followed by ChemoProton therapy plus capecitabine and oxaliplatin for locally advanced pancreatic cancer. J. Gastrointest. Oncol. 13, 1989\u20131996 (2022).","journal-title":"J. Gastrointest. Oncol."},{"key":"2705_CR312","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.gendis.2014.10.004","volume":"2","author":"SK Denduluri","year":"2015","unstructured":"Denduluri, S. K. et al. Insulin-like growth factor (IGF) signaling in tumorigenesis and the development of cancer drug resistance. Genes Dis. 2, 13\u201325 (2015).","journal-title":"Genes Dis."},{"key":"2705_CR313","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s13045-018-0616-2","volume":"11","author":"R Abdel-Wahab","year":"2018","unstructured":"Abdel-Wahab, R. et al. Randomized, phase I\/II study of gemcitabine plus IGF-1R antagonist (MK-0646) versus gemcitabine plus erlotinib with and without MK-0646 for advanced pancreatic adenocarcinoma. J. Hematol. Oncol. 11, 71 (2018).","journal-title":"J. Hematol. Oncol."},{"key":"2705_CR314","doi-asserted-by":"publisher","DOI":"10.1016\/j.neo.2024.101070","volume":"59","author":"S Han","year":"2025","unstructured":"Han, S. et al. A novel regimen for pancreatic ductal adenocarcinoma targeting MEK, BCL-xL, and EGFR. Neoplasia 59, 101070 (2025).","journal-title":"Neoplasia"},{"key":"2705_CR315","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s13046-025-03323-9","volume":"44","author":"Z Hong","year":"2025","unstructured":"Hong, Z. et al. Reciprocal regulation of MMP-28 and EGFR is required for sustaining proliferative signaling in PDAC. J. Exp. Clin. Cancer Res. 44, 68 (2025).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"2705_CR316","doi-asserted-by":"publisher","first-page":"175586","DOI":"10.1016\/j.ejphar.2023.175586","volume":"949","author":"S Ghalehbandi","year":"2023","unstructured":"Ghalehbandi, S., Yuzugulen, J., Pranjol, M. Z. I. & Pourgholami, M. H. The role of VEGF in cancer-induced angiogenesis and research progress of drugs targeting VEGF. Eur. J. Pharmacol. 949, 175586 (2023).","journal-title":"Eur. J. Pharmacol."},{"key":"2705_CR317","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.70653","volume":"14","author":"F Wang","year":"2025","unstructured":"Wang, F. et al. Safety, pharmacokinetics, and pharmacodynamics evaluation of ivonescimab, a novel bispecific antibody targeting PD-1 and VEGF, in chinese patients with advanced solid tumors. Cancer Med. 14, e70653 (2025).","journal-title":"Cancer Med."},{"key":"2705_CR318","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1530\/ERC-21-0239","volume":"29","author":"MH Kulke","year":"2022","unstructured":"Kulke, M. H. et al. Everolimus with or without bevacizumab in advanced pNET: CALGB 80701 (Alliance). Endocr. Relat. Cancer 29, 335\u2013344 (2022).","journal-title":"Endocr. Relat. Cancer"},{"key":"2705_CR319","doi-asserted-by":"publisher","first-page":"oyae364","DOI":"10.1093\/oncolo\/oyae364","volume":"30","author":"K Perez","year":"2025","unstructured":"Perez, K. et al. A phase II study of ramucirumab and somatostatin analog therapy in patients with advanced neuroendocrine tumors. Oncologist 30, oyae364 (2025).","journal-title":"Oncologist"},{"key":"2705_CR320","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1001\/jamaoncol.2022.0212","volume":"8","author":"DM Halperin","year":"2022","unstructured":"Halperin, D. M. et al. Assessment of clinical response following atezolizumab and bevacizumab treatment in patients with neuroendocrine tumors: a nonrandomized clinical trial. JAMA Oncol. 8, 904\u2013909 (2022).","journal-title":"JAMA Oncol."},{"key":"2705_CR321","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1042\/BST20170521","volume":"47","author":"S Lanfredini","year":"2019","unstructured":"Lanfredini, S., Thapa, A. & O\u2019Neill, E. RAS in pancreatic cancer. Biochem. Soc. Trans. 47, 961\u2013972 (2019).","journal-title":"Biochem. Soc. Trans."},{"key":"2705_CR322","doi-asserted-by":"publisher","DOI":"10.1186\/s13148-019-0681-6","volume":"11","author":"MW Chao","year":"2019","unstructured":"Chao, M. W. et al. Combination treatment strategy for pancreatic cancer involving the novel HDAC inhibitor MPT0E028 with a MEK inhibitor beyond K-Ras status. Clin. Epigenetics. 11, 85 (2019).","journal-title":"Clin. Epigenetics."},{"key":"2705_CR323","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1056\/NEJMoa2208470","volume":"388","author":"JH Strickler","year":"2023","unstructured":"Strickler, J. H. et al. Sotorasib in KRAS p.G12C-mutated advanced pancreatic cancer. N. Engl. J. Med. 388, 33\u201343 (2023).","journal-title":"N. Engl. J. Med."},{"key":"2705_CR324","doi-asserted-by":"publisher","first-page":"2768","DOI":"10.1038\/s41591-025-03688-6","volume":"31","author":"BC Cho","year":"2025","unstructured":"Cho, B. C. et al. D3S-001 in advanced solid tumors with KRAS(G12C) mutations: a phase 1 trial. Nat. Med. 31, 2768\u20132777 (2025).","journal-title":"Nat. Med."},{"key":"2705_CR325","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1002\/onco.13631","volume":"26","author":"EMJ van Brummelen","year":"2021","unstructured":"van Brummelen, E. M. J. et al. Phase I study of Afatinib and Selumetinib in patients with KRAS-mutated colorectal, non-small cell lung, and pancreatic cancer. Oncologist 26, 290\u2013e545 (2021).","journal-title":"Oncologist"},{"key":"2705_CR326","doi-asserted-by":"publisher","first-page":"109941","DOI":"10.1016\/j.radonc.2023.109941","volume":"190","author":"X Zhu","year":"2024","unstructured":"Zhu, X. et al. Immune profiling of pancreatic cancer for radiotherapy with immunotherapy and targeted therapy: biomarker analysis of a randomized phase 2 trial. Radiother. Oncol. 190, 109941 (2024).","journal-title":"Radiother. Oncol."},{"key":"2705_CR327","doi-asserted-by":"publisher","first-page":"4491","DOI":"10.1158\/0008-5472.CAN-18-3645","volume":"79","author":"A Jain","year":"2019","unstructured":"Jain, A. et al. Poly (ADP) ribose glycohydrolase can be effectively targeted in pancreatic cancer. Cancer Res. 79, 4491\u20134502 (2019).","journal-title":"Cancer Res."},{"key":"2705_CR328","doi-asserted-by":"publisher","first-page":"12555","DOI":"10.3390\/ijms241612555","volume":"24","author":"BG Dogaru","year":"2023","unstructured":"Dogaru, B. G. & Munteanu, C. The role of hydrogen sulfide (H(2)S) in epigenetic regulation of neurodegenerative diseases: a systematic review. Int. J. Mol. Sci. 24, 12555 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"2705_CR329","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1016\/j.apsb.2020.10.019","volume":"11","author":"X Hu","year":"2021","unstructured":"Hu, X. et al. New possible silver lining for pancreatic cancer therapy: hydrogen sulfide and its donors. Acta Pharm. Sin. B. 11, 1148\u20131157 (2021).","journal-title":"Acta Pharm. Sin. B."},{"key":"2705_CR330","doi-asserted-by":"publisher","first-page":"5928","DOI":"10.1158\/1538-7445.AM2024-5928","volume":"84","author":"AA Ahmed","year":"2024","unstructured":"Ahmed, A. A., Haider, S., Arshad, T. & Neidle, S. Structure-activity relationships for the pan-quadruplex experimental drug QN-302 and two analogs probed with comparative transcriptome profiling and molecular modeling. Cancer Res. 84, 5928\u20135928 (2024).","journal-title":"Cancer Res."},{"key":"2705_CR331","doi-asserted-by":"publisher","first-page":"6403","DOI":"10.1002\/cam4.2384","volume":"8","author":"W Luo","year":"2019","unstructured":"Luo, W. et al. Novel discoveries targeting gemcitabine-based chemoresistance and new therapies in pancreatic cancer: How far are we from the destination?. Cancer Med. 8, 6403\u20136413 (2019).","journal-title":"Cancer Med."},{"key":"2705_CR332","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1007\/s12272-021-01359-x","volume":"44","author":"SJ Park","year":"2021","unstructured":"Park, S. J. et al. ACY-241, an HDAC6 inhibitor, overcomes erlotinib resistance in human pancreatic cancer cells by inducing autophagy. Arch. Pharm. Res. 44, 1062\u20131075 (2021).","journal-title":"Arch. Pharm. Res."},{"key":"2705_CR333","doi-asserted-by":"publisher","first-page":"2268","DOI":"10.3390\/ijms23042268","volume":"23","author":"MA Romeo","year":"2022","unstructured":"Romeo, M. A. et al. VPA and TSA interrupt the interplay between mutp53 and HSP70, leading to CHK1 and RAD51 down-regulation and sensitizing pancreatic cancer cells to AZD2461 PARP Inhibitor. Int. J. Mol. Sci. 23, 2268 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"2705_CR334","doi-asserted-by":"publisher","first-page":"5612","DOI":"10.1158\/0008-5472.CAN-19-0187","volume":"79","author":"C Mottini","year":"2019","unstructured":"Mottini, C. et al. Predictive signatures inform the effective repurposing of decitabine to treat KRAS\u2013dependent pancreatic ductal adenocarcinoma. Cancer Res. 79, 5612\u20135625 (2019).","journal-title":"Cancer Res."},{"key":"2705_CR335","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/cddiscovery.2015.10","volume":"1","author":"H Sugimoto","year":"2015","unstructured":"Sugimoto, H. et al. Silencing of RUNX2 enhances gemcitabine sensitivity of p53-deficient human pancreatic cancer AsPC-1 cells through the stimulation of TAp63-mediated cell death. Cell Death Discov. 1, 1\u201310 (2015).","journal-title":"Cell Death Discov."},{"key":"2705_CR336","doi-asserted-by":"publisher","first-page":"116492","DOI":"10.1016\/j.bcp.2024.116492","volume":"229","author":"M Espona-Fiedler","year":"2024","unstructured":"Espona-Fiedler, M. et al. Overcoming therapy resistance in pancreatic cancer: new insights and future directions. Biochem. Pharmacol. 229, 116492 (2024).","journal-title":"Biochem. Pharmacol."},{"key":"2705_CR337","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1038\/s41568-025-00824-9","volume":"25","author":"A Soragni","year":"2025","unstructured":"Soragni, A. et al. Acquired resistance in cancer: towards targeted therapeutic strategies. Nat. Rev. Cancer 25, 613\u2013633 (2025).","journal-title":"Nat. Rev. Cancer"},{"key":"2705_CR338","doi-asserted-by":"publisher","first-page":"5680","DOI":"10.62347\/RLVZ6860","volume":"14","author":"Y Wang","year":"2024","unstructured":"Wang, Y. et al. NRP1 overexpression potentially enhances osimertinib resistance in NSCLC via activation of the PI3K\/AKT signaling pathway. Am. J. Cancer Res. 14, 5680\u20135696 (2024).","journal-title":"Am. J. Cancer Res."},{"key":"2705_CR339","doi-asserted-by":"publisher","first-page":"51a","DOI":"10.1016\/j.bpj.2019.11.458","volume":"118","author":"R Nussinov","year":"2020","unstructured":"Nussinov, R., Zhang, M. & Jang, H. RAS signaling in the PI3K\/AKT\/MTOR Pathway. Biophys. J. 118, 51a (2020).","journal-title":"Biophys. J."},{"key":"2705_CR340","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-25728-8","volume":"12","author":"J Br\u00e4gelmann","year":"2021","unstructured":"Br\u00e4gelmann, J. et al. MAPK-pathway inhibition mediates inflammatory reprogramming and sensitizes tumors to targeted activation of innate immunity sensor RIG-I. Nat. Commun. 12, 5505 (2021).","journal-title":"Nat. Commun."},{"key":"2705_CR341","doi-asserted-by":"publisher","first-page":"e70295","DOI":"10.1002\/mco2.70295","volume":"6","author":"M Jiang","year":"2025","unstructured":"Jiang, M. et al. PI3K\/AKT\/mTOR axis in cancer: from pathogenesis to treatment. MedComm 6, e70295 (2025).","journal-title":"MedComm"},{"key":"2705_CR342","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.3390\/ijms13011186","volume":"13","author":"D Chen","year":"2012","unstructured":"Chen, D. et al. Inhibition of AKT2 enhances sensitivity to gemcitabine via regulating PUMA and NF-\u03baB signaling pathway in human pancreatic ductal adenocarcinoma. Int. J. Mol. Sci. 13, 1186\u20131208 (2012).","journal-title":"Int. J. Mol. Sci."},{"key":"2705_CR343","doi-asserted-by":"publisher","first-page":"275","DOI":"10.3390\/biom15020275","volume":"15","author":"R Dieli","year":"2025","unstructured":"Dieli, R. et al. The Oncoprotein Mucin 1 in pancreatic cancer onset and progression: potential clinical implications. Biomolecules 15, 275 (2025).","journal-title":"Biomolecules"},{"key":"2705_CR344","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1038\/onc.2012.179","volume":"32","author":"N Skrypek","year":"2013","unstructured":"Skrypek, N. et al. The MUC4 mucin mediates gemcitabine resistance of human pancreatic cancer cells via the Concentrative Nucleoside Transporter family. Oncogene 32, 1714\u20131723 (2013).","journal-title":"Oncogene"},{"key":"2705_CR345","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1038\/s41577-022-00829-7","volume":"23","author":"FT Liu","year":"2023","unstructured":"Liu, F. T. & Stowell, S. R. The role of galectins in immunity and infection. Nat. Rev. Immunol. 23, 479\u2013494 (2023).","journal-title":"Nat. Rev. Immunol."},{"key":"2705_CR346","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.1016\/j.drudis.2020.09.037","volume":"25","author":"B Farran","year":"2020","unstructured":"Farran, B. & Nagaraju, G. P. Exosomes as therapeutic solutions for pancreatic cancer. Drug Discov. Today 25, 2245\u20132256 (2020).","journal-title":"Drug Discov. Today"},{"key":"2705_CR347","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.cytogfr.2025.10.004","volume":"86","author":"R Malla","year":"2025","unstructured":"Malla, R., Mangam, C. & Nagaraju, G. P. Pancreatic cancer exosomes: their role in drug resistance and immunomodulation. Cytokine Growth Factor Rev. 86, 108\u2013120 (2025).","journal-title":"Cytokine Growth Factor Rev."},{"key":"2705_CR348","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/978-1-4939-3347-1_13","volume":"1395","author":"R Andr\u00e9 Mdo","year":"2016","unstructured":"Andr\u00e9 Mdo, R., Pedro, A. & Lyden, D. Cancer exosomes as mediators of drug resistance. Methods Mol. Biol. 1395, 229\u2013239 (2016).","journal-title":"Methods Mol. Biol."},{"key":"2705_CR349","doi-asserted-by":"publisher","first-page":"361","DOI":"10.15698\/cst2019.12.205","volume":"3","author":"JT Li","year":"2019","unstructured":"Li, J. T., Wang, Y. P., Yin, M. & Lei, Q. Y. Metabolism remodeling in pancreatic ductal adenocarcinoma. Cell Stress. 3, 361\u2013368 (2019).","journal-title":"Cell Stress."},{"key":"2705_CR350","doi-asserted-by":"publisher","first-page":"3591","DOI":"10.1038\/s41388-023-02869-2","volume":"42","author":"P Fan","year":"2023","unstructured":"Fan, P. et al. Alleviating hypoxia to improve cancer immunotherapy. Oncogene 42, 3591\u20133604 (2023).","journal-title":"Oncogene"},{"key":"2705_CR351","doi-asserted-by":"publisher","first-page":"e2315509121","DOI":"10.1073\/pnas.2315509121","volume":"121","author":"D Murthy","year":"2024","unstructured":"Murthy, D. et al. The MUC1-HIF-1\u03b1 signaling axis regulates pancreatic cancer pathogenesis through polyamine metabolism remodeling. Proc. Natl. Acad. Sci. USA 121, e2315509121 (2024).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2705_CR352","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-021-04116-6","volume":"12","author":"K Chen","year":"2021","unstructured":"Chen, K. et al. The metabolic flexibility of quiescent CSC: implications for chemotherapy resistance. Cell Death Dis. 12, 835 (2021).","journal-title":"Cell Death Dis."},{"key":"2705_CR353","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-38401-z","volume":"14","author":"J-M Park","year":"2023","unstructured":"Park, J.-M., Lee, D.-H. & Kim, D.-H. Redefining the role of AMPK in autophagy and the energy stress response. Nat. Commun. 14, 2994 (2023).","journal-title":"Nat. Commun."},{"key":"2705_CR354","doi-asserted-by":"publisher","first-page":"39","DOI":"10.21037\/tgh-23-27","volume":"8","author":"E Sarfaty","year":"2023","unstructured":"Sarfaty, E. et al. Surgical management of pancreatic ductal adenocarcinoma: a narrative review. Transl. Gastroenterol. Hepatol. 8, 39 (2023).","journal-title":"Transl. Gastroenterol. Hepatol."},{"key":"2705_CR355","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1016\/j.ciresp.2022.10.020","volume":"101","author":"S Sent\u00ed Farrarons","year":"2023","unstructured":"Sent\u00ed Farrarons, S. et al. Venous resection in pancreatic oncologic surgery: different techniques for different situations. Cir. Esp. (Engl. Ed.). 101, 816\u2013823 (2023).","journal-title":"Cir. Esp. (Engl. Ed.)."},{"key":"2705_CR356","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1097\/CCO.0000000000000639","volume":"32","author":"L Mas","year":"2020","unstructured":"Mas, L., Schwarz, L. & Bachet, J. B. Adjuvant chemotherapy in pancreatic cancer: state of the art and future perspectives. Curr. Opin. Oncol. 32, 356\u2013363 (2020).","journal-title":"Curr. Opin. Oncol."},{"key":"2705_CR357","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1002\/ijc.33916","volume":"150","author":"EJM de Jong","year":"2022","unstructured":"de Jong, E. J. M. et al. Real-world evidence of adjuvant gemcitabine plus capecitabine vs gemcitabine monotherapy for pancreatic ductal adenocarcinoma. Int. J. Cancer 150, 1654\u20131663 (2022).","journal-title":"Int. J. Cancer"},{"key":"2705_CR358","doi-asserted-by":"publisher","first-page":"29","DOI":"10.3233\/JRS-210015","volume":"34","author":"K Bauer","year":"2023","unstructured":"Bauer, K., Henne-Bruns, D. & Manzini, G. Analysis of the CONKO-001 trial: is the validity of the study sufficient to recommend adjuvant chemotherapy for pancreatic cancer?. Int. J. Risk Saf. Med. 34, 29\u201340 (2023).","journal-title":"Int. J. Risk Saf. Med."},{"key":"2705_CR359","doi-asserted-by":"publisher","first-page":"7055","DOI":"10.3390\/ijms26157055","volume":"26","author":"S Peshin","year":"2025","unstructured":"Peshin, S. et al. Advances in the management of pancreatic cancer: current strategies and emerging therapies. Int. J. Mol. Sci. 26, 7055 (2025).","journal-title":"Int. J. Mol. Sci."},{"key":"2705_CR360","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.1200\/JCO.19.00075","volume":"37","author":"WZ Zhong","year":"2019","unstructured":"Zhong, W. Z. et al. Erlotinib versus gemcitabine plus Cisplatin as Neoadjuvant treatment of stage IIIA-N2 EGFR-mutant non-small-cell lung cancer (EMERGING-CTONG 1103): a randomized phase II study. J. Clin. Oncol. 37, 2235\u20132245 (2019).","journal-title":"J. Clin. Oncol."},{"key":"2705_CR361","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.1200\/JCO.22.01134","volume":"41","author":"MA Tempero","year":"2023","unstructured":"Tempero, M. A. et al. Adjuvant nab-Paclitaxel + Gemcitabine in resected pancreatic ductal adenocarcinoma: results from a randomized, open-label, phase III trial. J. Clin. Oncol. 41, 2007\u20132019 (2023).","journal-title":"J. Clin. Oncol."},{"key":"2705_CR362","doi-asserted-by":"publisher","first-page":"216382","DOI":"10.1016\/j.canlet.2023.216382","volume":"573","author":"J Natu","year":"2023","unstructured":"Natu, J. & Nagaraju, G. P. Gemcitabine effects on tumor microenvironment of pancreatic ductal adenocarcinoma: special focus on resistance mechanisms and metronomic therapies. Cancer Lett. 573, 216382 (2023).","journal-title":"Cancer Lett."},{"key":"2705_CR363","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1093\/jnci\/djae269","volume":"117","author":"F Keane","year":"2025","unstructured":"Keane, F. et al. Adjuvant modified FOLFIRINOX for resected pancreatic adenocarcinoma: clinical insights and genomic features from a large contemporary cohort. J. Natl. Cancer Inst. 117, 496\u2013506 (2025).","journal-title":"J. Natl. Cancer Inst."},{"key":"2705_CR364","doi-asserted-by":"publisher","first-page":"751110","DOI":"10.3389\/fmed.2021.751110","volume":"8","author":"IJM Levink","year":"2021","unstructured":"Levink, I. J. M. et al. Neoantigen quantity and quality in relation to pancreatic cancer survival. Front. Med. 8, 751110 (2021).","journal-title":"Front. Med."},{"key":"2705_CR365","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1038\/s41401-020-00584-2","volume":"42","author":"H-f Hu","year":"2021","unstructured":"Hu, H. -f et al. Mutations in key driver genes of pancreatic cancer: molecularly targeted therapies and other clinical implications. Acta Pharm. Sin. 42, 1725\u20131741 (2021).","journal-title":"Acta Pharm. Sin."},{"key":"2705_CR366","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1007\/s10555-020-09911-9","volume":"39","author":"Z Orgov\u00e1n","year":"2020","unstructured":"Orgov\u00e1n, Z. & Keser\u0171, G. M. Small molecule inhibitors of RAS proteins with oncogenic mutations. Cancer Metastasis Rev. 39, 1107\u20131126 (2020).","journal-title":"Cancer Metastasis Rev."},{"key":"2705_CR367","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1158\/1078-0432.CCR-23-2098","volume":"30","author":"D Wei","year":"2024","unstructured":"Wei, D. et al. A small molecule with big impact: MRTX1133 targets the KRASG12D mutation in pancreatic cancer. Clin. Cancer Res. 30, 655\u2013662 (2024).","journal-title":"Clin. Cancer Res."},{"key":"2705_CR368","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1056\/NEJMoa1917239","volume":"383","author":"DS Hong","year":"2020","unstructured":"Hong, D. S. et al. KRAS(G12C) inhibition with sotorasib in advanced solid tumors. N. Engl. J. Med. 383, 1207\u20131217 (2020).","journal-title":"N. Engl. J. Med."},{"key":"2705_CR369","doi-asserted-by":"publisher","first-page":"e202000875","DOI":"10.26508\/lsa.202000875","volume":"4","author":"KM McAndrews","year":"2021","unstructured":"McAndrews, K. M. et al. Exosome-mediated delivery of CRISPR\/Cas9 for targeting of oncogenic Kras(G12D) in pancreatic cancer. Life Sci. Alliance 4, e202000875 (2021).","journal-title":"Life Sci. Alliance"},{"key":"2705_CR370","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1093\/jb\/mvaf022","volume":"178","author":"Y Kudo","year":"2025","unstructured":"Kudo, Y. et al. Inhibition of autophagy by Atg7 knockdown enhances chemosensitivity in gemcitabine\/paclitaxel-resistant pancreatic cancer MIAPaCa2 cells. J. Biochem. 178, 11\u201324 (2025).","journal-title":"J. Biochem."},{"key":"2705_CR371","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-025-07720-y","volume":"16","author":"T Ma","year":"2025","unstructured":"Ma, T. et al. Tumor-derived exosomal CCT6A serves as a matchmaker introducing chemokines to tumor-associated macrophages in pancreatic ductal adenocarcinoma. Cell Death Dis. 16, 382 (2025).","journal-title":"Cell Death Dis."},{"key":"2705_CR372","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-025-02683-8","volume":"42","author":"M-W Hao","year":"2025","unstructured":"Hao, M.-W. et al. Enhancing KRAS G12D inhibitor sensitivity in pancreatic cancer through SHP2\/PI3K pathway. Med. Oncol. 42, 139 (2025).","journal-title":"Med. Oncol."},{"key":"2705_CR373","doi-asserted-by":"publisher","unstructured":"Ge, X. et al. Phosphoinositide 3-kinase regulates wild-type RAS signaling to confer resistance to KRAS inhibition. Preprint at https:\/\/doi.org\/10.1101\/2025.06.20.660715 (2025).","DOI":"10.1101\/2025.06.20.660715"},{"key":"2705_CR374","first-page":"100206","volume":"7","author":"AMW Hasan","year":"2025","unstructured":"Hasan, A. M. W. et al. Quercetin promises anticancer activity through PI3K-AKT-mTOR pathway: a literature review. Pharm. Res. Nat. Prod. 7, 100206 (2025).","journal-title":"Pharm. Res. Nat. Prod."},{"key":"2705_CR375","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-024-00793-6","volume":"9","author":"K Maruyama","year":"2025","unstructured":"Maruyama, K. et al. Mechanisms of KRAS inhibitor resistance in KRAS-mutant colorectal cancer harboring Her2 amplification and aberrant KRAS localization. NPJ Precis. Oncol. 9, 4 (2025).","journal-title":"NPJ Precis. Oncol."},{"key":"2705_CR376","doi-asserted-by":"publisher","first-page":"776","DOI":"10.3390\/biology14070776","volume":"14","author":"V Porreca","year":"2025","unstructured":"Porreca, V. et al. ERK1\/2 signaling in intrahepatic cholangiocarcinoma: from preclinical advances to therapeutic strategies. Biology 14, 776 (2025).","journal-title":"Biology"},{"key":"2705_CR377","doi-asserted-by":"publisher","first-page":"e70250","DOI":"10.1002\/mco2.70250","volume":"6","author":"J Tan","year":"2025","unstructured":"Tan, J. et al. Neobractatin and Trametinib SYNERGISTICALLY INDUCE APOPTOsis and Gasdermin E-DEPENDENT PYROPTOSIS IN PANCREATIC CANCER CElls. MedComm 6, e70250 (2025).","journal-title":"MedComm"},{"key":"2705_CR378","doi-asserted-by":"publisher","first-page":"OF1","DOI":"10.1158\/1535-7163.MCT-24-0831","volume":"24","author":"E Toyokuni","year":"2025","unstructured":"Toyokuni, E. et al. Combination therapy of avutometinib and MRTX1133 synergistically suppresses cell growth by inducing apoptosis in KRASG12D-mutated pancreatic cancer. Mol. Cancer Ther. 24, OF1\u2013OF9 (2025).","journal-title":"Mol. Cancer Ther."},{"key":"2705_CR379","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-025-01046-w","volume":"9","author":"R Bhatia","year":"2025","unstructured":"Bhatia, R. et al. Targeting cancer-associated fibroblast-driven LIF\/LIFR axis improves the therapeutic efficacy of gemcitabine and nab-paclitaxel in pancreatic cancer. NPJ Precis. Oncol. 9, 296 (2025).","journal-title":"NPJ Precis. Oncol."},{"key":"2705_CR380","doi-asserted-by":"publisher","first-page":"2949","DOI":"10.1021\/acs.nanolett.4c06372","volume":"25","author":"S Zhang","year":"2025","unstructured":"Zhang, S. et al. Transcytosis-triggering nanoparticles for overcoming stromal barriers and reversing immunosuppression in pancreatic cancer combinatorial therapy. Nano Lett. 25, 2949\u20132959 (2025).","journal-title":"Nano Lett."},{"key":"2705_CR381","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1016\/j.semcancer.2021.06.014","volume":"86","author":"BP Girish","year":"2022","unstructured":"Girish, B. P. et al. Targeting the tumor microenvironment of pancreatic ductal adenocarcinoma using nano-phytomedicines. Semin. Cancer Biol. 86, 1155\u20131162 (2022).","journal-title":"Semin. Cancer Biol."},{"key":"2705_CR382","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.3390\/biomedicines12102175","volume":"12","author":"B Li","year":"2024","unstructured":"Li, B., Zhang, Q., Castaneda, C. & Cook, S. Targeted therapies in pancreatic cancer: a new era of precision medicine. Biomedicines 12, 2175 (2024).","journal-title":"Biomedicines"},{"key":"2705_CR383","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-025-02364-0","volume":"24","author":"X Wang","year":"2025","unstructured":"Wang, X. et al. Evolution of direct RAS inhibitors: from undruggable target to clinical breakthroughs. Mol. Cancer 24, 229 (2025).","journal-title":"Mol. Cancer"},{"key":"2705_CR384","doi-asserted-by":"publisher","first-page":"176727","DOI":"10.1016\/j.ejphar.2024.176727","volume":"979","author":"MA Hossain","year":"2024","unstructured":"Hossain, M. A. Targeting the RAS upstream and downstream signaling pathway for cancer treatment. Eur. J. Pharmacol. 979, 176727 (2024).","journal-title":"Eur. J. Pharmacol."},{"key":"2705_CR385","doi-asserted-by":"publisher","first-page":"e135","DOI":"10.1016\/S1470-2045(19)30795-8","volume":"21","author":"ES Christenson","year":"2020","unstructured":"Christenson, E. S., Jaffee, E. & Azad, N. S. Current and emerging therapies for patients with advanced pancreatic ductal adenocarcinoma: a bright future. Lancet Oncol. 21, e135\u2013e145 (2020).","journal-title":"Lancet Oncol."},{"key":"2705_CR386","doi-asserted-by":"publisher","first-page":"103465","DOI":"10.1016\/j.critrevonc.2021.103465","volume":"166","author":"K Umemoto","year":"2021","unstructured":"Umemoto, K. & Sunakawa, Y. The potential targeted drugs for fusion genes including NRG1 in pancreatic cancer. Crit. Rev. Oncol. Hematol. 166, 103465 (2021).","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"2705_CR387","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.31557\/APJCP.2025.26.6.1931","volume":"26","author":"S Devi","year":"2025","unstructured":"Devi, S. & Chandrababu, R. Impact of Olaparib, Niraparib, Rucaparib therapies on newly diagnosed and relapsed ovarian cancer -systematic review and meta-analysis. Asian Pac. J. Cancer Prev. 26, 1931\u20131941 (2025).","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"2705_CR388","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1038\/s41422-025-01098-4","volume":"35","author":"K Wang","year":"2025","unstructured":"Wang, K. et al. Nociceptor neurons promote PDAC progression and cancer pain by interaction with cancer-associated fibroblasts and suppression of natural killer cells. Cell Res. 35, 362\u2013380 (2025).","journal-title":"Cell Res."},{"key":"2705_CR389","doi-asserted-by":"publisher","first-page":"4018","DOI":"10.1158\/1078-0432.CCR-25-1201","volume":"31","author":"D Wei","year":"2025","unstructured":"Wei, D. et al. CAR-macrophage cell therapy: a new era of hope for pancreatic cancer. Clin. Cancer Res. 31, 4018\u20134031 (2025).","journal-title":"Clin. Cancer Res."},{"key":"2705_CR390","doi-asserted-by":"publisher","DOI":"10.1186\/s12951-024-03010-5","volume":"22","author":"A Palencia-Campos","year":"2024","unstructured":"Palencia-Campos, A. et al. Reprogramming tumor-associated macrophages with lipid nanosystems reduces PDAC tumor burden and liver metastasis. J. Nanobiotechnol. 22, 795 (2024).","journal-title":"J. Nanobiotechnol."},{"key":"2705_CR391","doi-asserted-by":"publisher","first-page":"3774","DOI":"10.1038\/s41388-025-03530-w","volume":"44","author":"X Zou","year":"2025","unstructured":"Zou, X. et al. ALDH1A3 promotes aggressive basal-like pancreatic cancer through an AP-1\/RUNX2 enhancer network. Oncogene 44, 3774\u20133786 (2025).","journal-title":"Oncogene"},{"key":"2705_CR392","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-025-07835-2","volume":"16","author":"J Chen","year":"2025","unstructured":"Chen, J. et al. Targeted delivery of the PKMYT1 inhibitor RP-6306 mediates PANoptosis in pancreatic cancer via mitotic catastrophe. Cell Death Dis. 16, 526 (2025).","journal-title":"Cell Death Dis."},{"key":"2705_CR393","doi-asserted-by":"publisher","first-page":"5650","DOI":"10.1158\/1538-7445.AM2022-5650","volume":"82","author":"J Fourtounis","year":"2022","unstructured":"Fourtounis, J. et al. RP-6306, a novel PKMYT1 inhibitor, demonstrates synthetic lethality as monotherapy and in combination with gemcitabine in CCNE1 amplified cancer cells. Cancer Res. 82, 5650\u20135650 (2022).","journal-title":"Cancer Res."}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02705-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02705-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02705-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T00:01:42Z","timestamp":1777939302000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02705-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,5]]},"references-count":393,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2705"],"URL":"https:\/\/doi.org\/10.1038\/s41392-026-02705-5","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,5]]},"assertion":[{"value":"23 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 December 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"165"}}